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Abstract 
 
Development of an Organocatalytic Method for the Enantioselective Synthesis of 
Rivastigmine 
 
The focus of this thesis was the study of a recently developed class of picolinamide 
cinchona alkaloid derivatives for the synthesis of Rivastigmine, a biologically active 
compound used for the treatment of Alzheimer’s disease.  
Six 9-picolinamide-cinchona alkaloid derivatives were successfully synthesized through 
simple and effective methods. These catalysts were then applied in the enantioselective 
reduction of O-protected ketimines (intermediates of Rivastigmine). The hydrosilylation of 
the N-phenyl ketimines afforded good results with excellent yields and high 
enantioselectivities, while much lower values, in terms of both enantioselectivity and yield, 
were obtained in the reduction of N-benzyl ketimines. 
Preliminary studies on the immobilization of these organocatalysts to different solid 
supports were conducted, with the purpose of applying them in continuous flow systems, 
which to date has never been reported.   
 
 
 
 
 
 
 
 
 
Keywords: Ketimine reduction, Chiral amines, Cinchona alkaloid derivatives, Rivastigmine. 
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Resumo 
 
Desenvolvimento de um Método Organocatalítico para a Síntese Enantiosseletiva 
de Rivastigmina 
 
No âmbito deste trabalho, foi estudada a síntese de um composto biologicamente ativo 
usado para o tratamento da doença de Alzheimer, Rivastigmina, usando uma classe de 
picolinamidas derivadas de alcaloides de cinchona recentemente desenvolvida.  
Seis 9-picolinamida derivados de alcaloides de cinchona foram preparados com êxito 
através de metodologias simples e eficazes. Os organocatalisadores foram posteriormente 
aplicados na redução enantiosseletiva de cetiminas O-protegidas (intermediários de 
Rivastigmina). Foram obtidos bons resultados na hidrossililação de N-fenilo cetiminas, com 
rendimentos excelentes e elevadas enantiosseletividades, enquanto a redução de N-
benzilo cetiminas proporcionou valores muito mais baixos, tanto em termos de rendimento 
como de enantiosseletividade.  
Com o objetivo de serem aplicados em sistemas de fluxo contínuo, realizaram-se 
estudos preliminares sobre a imobilização destes organocatalisadores em diferentes 
suportes sólidos, a qual, ate à data, ainda não foi descrita na literatura.   
 
 
 
 
 
 
 
 
 
Palavras-chave: Redução de cetiminas, Aminas quirais, Derivados de alcaloides de 
cinchona, Rivastigmina.   
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“Nothing in life is to be feared, it is only to be understood. Now is the time to understand 
more, so that we may fear less” 
Marie Curie 
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In the last few decades, neurodegenerative diseases have become a worldwide worrying 
issue, due to the significant ageing of the world population. Currently, Alzheimer’s disease 
(AD) is the most common neurodegenerative disease, there being about 35 million people 
worldwide suffering from this disease, a number that is expected to increase 3 to 4 times 
before 2050.1 Indeed, AD has become a public health issue on a global scale and there is 
no cure for it. However, there are some therapeutic strategies available to treat the 
symptoms associated with AD.2 
Many of the current drugs used to treat these diseases, such as Rivastigmine and 
Amgen’s hydroxyethylamine-based secretase inhibitor, possess a chiral amine unit in their 
structure.3 Thus there is an increasing interest in the development of more efficient methods 
to obtain these chiral amine units. Inducing chirality during chemical synthesis by catalytic 
methods represents one of the most important fields in modern organic chemistry. Among 
the various approaches to achieve this objective, the use of chiral organocatalysts 
represents a particularly appealing strategy, because the enantiomeric control is often 
achieved by the simple combination of purely organic catalysts with the substrate/reagent, 
without the possibility of any metal residues in the final product. Indeed, in the last two 
decades, organocatalysis has emerged as an attractive and efficient alternative to the so 
called conventional catalytic methods – transition metal-based catalysis and biocatalysis.4 
The main industrial process for the preparation of chiral amines is via catalytic 
asymmetric hydrogenation of imines. Currently, this preparation is mainly done employing 
transition metal-based catalysts, which makes the process very expensive and wasteful, as 
well as increases the possible toxicity of the final product.5 The hydrosilylation of ketimines 
with an active efficient organocatalyst and trichlorosilane is a very attractive alternative. 
Thrichlorosilane mediated reductions are especially attractive from the pharmaceutical point 
of view, due to the low cost of the reagent.6  
The main objective of this project is the development of a new and more efficient 
organocatalytic synthetic pathway for the preparation of drugs used in AD treatment, more 
specifically Rivastigmine. We employed a recently developed and highly active class of 
organocatalysts – cinchona-derived picolinamides7 – in the hydrosilylation of ketimine 
intermediates of Rivastigmine (derived mainly from 3’-hydroxyacetophenone). Besides the 
homogenous version of this synthetic system, we did some preliminary work in its 
heterogeneous counterpart, with the immobilization of these catalysts to the solid phase. 
This was done in order to apply enabling technologies, such as flow chemistry8, in the 
hydrosilylation reactions.  
Dissertation Overview 
 
 
4 
 
This dissertation is divided in four main parts. First, we present the theoretical background 
of organocatalysis, were we give a comprehensive, but brief global overview of the literature 
published to date. This is followed by the presentation and discussion of the complete 
laboratorial results obtained during the execution of this project, divided by preparation of 
organocatalysts, preparation of ketimine precursors and, lastly, the application of the 
catalysts in the hydrosilylation of the prepared imines. Thirdly, we show the conclusions 
obtained during this project, as well as some future perspectives for its continuation. And 
lastly, but definitely not least, the experimental procedures used for the synthesis of 
organocatalysts, of ketimine intermediates and catalytic reactions are gathered, as well as 
the characterization of the obtained products. All the bibliographical references used for the 
preparation of this dissertation are shown at the end.  
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1. Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Science is like a love affair with nature; an elusive, tantalizing mistress. It has all the 
turbulence, twists and turns of romantic love, but that’s part of the game” 
Vilayanur Ramachandran 
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1.1 Organocatalysis 
 
1.1.1 Overview  
 
The enantioselective production of compounds is a central theme in current research. 
One of the main objectives of organic chemists resides in the study and development of 
methodologies to provide valuable products from readily available starting materials.1-4 In 
organic chemistry, valuable products are usually associated with enantiomerically enriched 
products due to the unique properties presented by each enantiomer of a racemic mixture.5 
In the past two decades the number of methods available for high yielding and 
enantioselective transformations of organic compounds has increased exponentially.6  
Currently the preparation of enantiopure compounds can be done mainly by three different 
methods – resolution of racemic mixtures, chiral pool synthesis or asymmetric catalysis. 
Traditionally, on the industrial scale, with some exceptions, this enantiopure compounds are 
obtained by resolution.7 However, this method presents some relatively serious gaps – the 
time constraints on discovery chemists and the potential waste of organic material, due to 
the limitation of the amount of enantiomer obtain that is naturally set at 50%. In some cases, 
the latter limitation can be reduced when the conversion of the opposite enantiomer into the 
desired one is possible, either by a dynamic kinetic resolution or by an alternative synthetic 
scheme, however increasing even more the time constraints.8 
Asymmetric synthesis, the ability of controlling the three dimensional structure of the 
molecular architecture, has assumed a featured role in the preparation of enantiopure 
compounds, and was responsible for revolutionizing chemistry in the second half of the XXth 
century.9 Asymmetric synthesis – which can be divided in a stoichiometric or catalytic 
approach – unlike the previous method, does not resolve racemic mixtures, but is in turn 
responsible for the creation of stereogenic centers, common feature of many natural and 
synthetic pharmaceutical agents.10 Asymmetric catalysis is a prominent area of 
investigation, since “a small amount of an enantiomerically pure catalyst, enzymatic or not, 
is used to produce large amounts of an optically active compound from a chiral or achiral 
precursor”,11 providing economic advantages as well as “atom economy”. Due to these 
advantages, the interest in this area has increased tremendously over the last five decades, 
and the development of efficient asymmetric catalytic systems for valuable organic 
transformations has been a main concern for organic chemists.12 Perhaps one of the best 
illustrations of the importance of asymmetric catalysis was the Nobel Prize in Chemistry 
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awarded in 2001 to three of the greatest chemists for their contributions to this area, namely 
to William R. Knowles13 and Ryoji Navori14 “for their work on chirally catalyzed hydrogenation 
reactions” and to K. Barry Sharpless15 “for his work on chirally catalyzed oxidation reaction”.  
Until recently, and due to all the developments and obtained results in this area, the 
catalysts employed for enantioselective synthesis of organic compounds fell into two general 
categories – transition metal complexes and enzymes. However, during the last decade, this 
dogma changed when several reports confirmed that relatively simple molecules, such as 
proline, could be highly effective and remarkably enantioselective catalysts of a variety of 
fundamentally important transformations. And so, between the extremes of transition metal 
catalysis and enzymatic transformations, a third approach to the catalytic production of 
enantiomerically pure organic compounds has emerged – Asymmetric Organocatalysis.1,5,9   
Organocatalysis, a relatively new and popular field of asymmetric catalysis, had its boom 
in the scientific community in the year 2000 mostly due to the work of two independent 
research groups and their respective publications. Both publications converged on the use 
of small molecular weight chiral molecules, without any metals in their structure, for the 
asymmetric synthesis of organic compounds. David MacMillan and his team16 used 
imidazolidinones as organocatalyst in the asymmetric version of the Diels-Alder 
cycloadditions, while Benjamin List and his team17 worked on enantioselective aldol 
reactions using L-proline as organocatalyst, in which both obtained very good results. 
MacMillan himself, in that same year, defined “Organocatalysis” as “the use of small 
molecular weight molecules to catalyze organic transformations”.16  
Organocatalysis provides a means of accelerating chemical reactions with a 
substoichiometric amount of organic molecules, which do not contain a metal element.9 
Organocatalysts can be defined as purely “organic” molecules, i.e. composed (mainly) of 
carbon, hydrogen, nitrogen, sulfur and phosphorus.5 Organocatalysts have several 
advantages that led to a complementary mode of catalysis, with the potential for savings in 
terms of costs, time and energy, reductions in chemical waste, and simplified experimental 
procedures. This benefits arise essentially from three factors. First, organic catalysts are 
generally insensitive to oxygen and moisture (i.e. not hygroscopic) in the atmosphere, so 
there is no need for special reaction conditions or storage, such as inert atmosphere, as well 
as for ultra-dry reagents and solvents. Second, a wide variety of organic molecules – such 
as amino acids, carbohydrates and hydroxy acids – are naturally available from biological 
sources as single enantiomers. Simple organocatalysts are therefore usually cheap to 
prepare and readily accessible in a wide range of quantities, making them suitable to work 
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in small-scale reactions as well as industrial-scale reactions. Third, because these catalysts 
do not possess any metal in their structure, these molecules are typically non-toxic and 
environmentally friendly, increasing the safety of the catalysis for both the operator and the 
environment, on an industrial and academic level.1819 
 Despite its rich historical past, the use of small organic molecules as chiral catalysts has 
only recently been recognized as a valuable addition and/or alternative to existing, well-
established, often metal-based methodologies in asymmetric synthesis. Organocatalysis 
has seen a tremendous rise in popularity, having captured the attention and curiosity of 
several research groups from all around the world.9,21 Enantioselective organocatalytic 
processes have reached maturity in recent years with an impressive and steadily increasing 
number of publications on the application of this type of reaction, which paints a 
comprehensive picture of their real possibilities in organic chemistry.20 In a little more than 
a decade after its boom, organocatalysis has expanded to practically every area of organic 
chemistry, from polymer synthesis,22,23 to total synthesis,24,25 being used in both 
homogenous and heterogeneous catalysis with catalysts being immobilized in several 
different types of supports. It has been used in numerous chemical transformations, such as 
addition, substitution, elimination and rearrangement reactions7. There doesn’t seem to be 
any limitations to the application of organocatalysis, except perhaps those imposed by the 
“person” working with it.  
  
 
1.1.2 Historical Background  
 
Even though organocatalysis has only recently established itself as an effective field of 
research, this was not be any means the “genesis” of organic catalysts. The history of 
organocatalytic reactions has a rich past, with evidence that such catalysis has in the past 
played a determinant role in the formation of prebiotic key building blocks such as sugars.26-
29 The year 2000 “only” marked the awakening of this very important area of chemistry, since 
organic molecules have been used as catalysts from the early age of synthetic chemistry. 
Indeed, the first reference of organic molecules with catalytic properties goes back to the 
XIXth century when in 1859 Justus von Liebig – accidentally – discovered that dicyan 1 is 
transformed into oxamide 2 in the presence of an aqueous solution of acetaldehyde 
(Scheme 1.1).9 
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Scheme 1.1 von Liebig's oxamide synthesis.9 
 
Undoubtedly, the discovery of enzymes and enzyme functions had an important impact 
on the development of asymmetric catalytic reactions. Despite Liebig’s reaction being 
catalyzed by an organic molecule, this was not the first described asymmetric reaction. The 
first asymmetric reaction – a decarboxylative kinetic resolution – is attributed to Louis 
Pasteur that, in 1853, introduced the term “dissymmetry”.30 Pasteur observed that the 
organism Penicillium glauca destroyed more rapidly one the enantiomers from a racemic 
resolution of ammonium tartrate.31,32 
In the beginning of the XXth century, asymmetric decarboxylation reactions were re-
examined under non-enzymatic conditions by Georg Bredig, a German scientist.  Bredig, 
who had a remarkably wide interdisciplinary interest, was motivated to find the chemical 
origin of enzyme activity observed in living organisms. He was able to establish the basic 
kinetic equations of the thermal decarboxylation of optically active camphorcarboxylic acid 
in d and l limonemes in the presence of chiral alkaloids, such as nicotine or quinine.33,34 
Based on Rosenthaler’s work35 – who was able to prepare mandelonitrile 4 by the addition 
of HCN to benzaldehyde 3 in the presence of an isolated enzyme, emulsin – Bredig became 
a pioneer by performing the first asymmetric C–C bond forming reaction. In 1912, Bredig 
and Fiske perform the same reaction as Rosenthaler, but in the presence of alkaloids as 
catalysts, such as the pseudo-enantiomeric quinine 5 and quinidine 6 (Scheme 1.2). 
Although these studies were considered groundbreaking, the enantioselectivity of the 
reaction was less than 10%.36 
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Scheme 1Erro! Não existe nenhum texto com o estilo especificado no documento..2 Mandelonitrile 
synthesis performed by Bredig and Fiske.36 
 
Although catalytic transformations gained increasing importance after the First World 
War, asymmetric reactions were at the time considered to be an academic curiosity. The 
reinvestigation of Bredig’s asymmetric cyanohydrin synthesis by Prelog during the mid-
1950s undoubtedly promoted the concept of asymmetric synthesis, and led the way for more 
efficient reactions. Only in 1960 synthetically useful levels of enantioselectivity were 
obtained, when Pracejus demonstrated that methyl phenyl ketene 7 could be converted to 
(-)-α-phenyl methylpropionate 8 using cinchona alkaloids as catalyst, more specifically O-
acetylquinine 9 (Scheme 1.3).37,38 This quite impressive result inspired the reinvestigation of 
other possible reaction types for the cinchona catalyst system.  
 
 
Scheme 1.3 Pracejus’s enantioselective ester synthesis from phenyl methyl ketene.37,38 
 
In early 1970s, perhaps one of the most famous key events in the history of 
organocatalytic reactions was reported – the discovery of an efficient L-proline-mediated 
asymmetric Robinson annulation, through the work developed by two independent research 
groups led by Zoltan G. Hajos, from Hoffmann-La Roche, and Rudolf Wiechert, from 
Schering AG. The reaction that became known has the Hajos-Parrish-Eder-Sauer-Wiechert 
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reaction (an intramolecular aldol reaction) (Scheme 1.4) allowed access to some key 
intermediates for the synthesis of natural products.39  
 
 
Scheme 1.4 L-proline-mediated Robinson annulation.39 
 
It all started in 1971 when Eder, Sauer and Wiechert reported a Robison annulation (a 
Michael addition followed by an intramolecular aldol condensation) using a catalytic amount 
of L-proline 10, that was enough to obtain the desired product with an 83% yield and 71% 
enantiomeric excess.40  Three years later, Hajos and Parrish were able to reproduce a 
similar reaction at lower temperatures and perform the dehydration step in isolation, 
obtaining the desired product with an astonishing 93% enantiomeric excess.39 
Although the L-proline-mediated annulation received a considerable synthetic and 
mechanistic interest, this field of chemistry remained inexplicably relatively dormant for 
about 20 years. There were some minor discoveries made during the late 1970s and 1980s, 
with the discovery of reactions which proceeded via ion-paring mechanisms41,42 and 
relatively efficient phase-transfer reactions by Merck.43,44 Only during the late 1990s, 
chemists starting turning their attention back to organocatalysis when Dan Yang,45 Scott 
Denmark46 and Yian Shi,47 with their respective research groups, used enantiomerically pure 
ketones to catalyze enantioselective epoxidations of simple alkenes, with good yields and 
up to 95% enantiomeric excess (Scheme 1.5).  
 
 
Scheme 1.5 Olefin asymmetric epoxidation catalyzed by chiral ketones.47 
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Sometime later, three independent research groups lead by M. Lipton48, Elias Corey49 
and Eric Jacobsen50 reported the first examples of catalysis mediated by hydrogen bonds, 
namely asymmetrical Strecker reactions (Scheme 1.6), while Miller51 and his team 
introduced the concept of kinetic resolution in alcohols with small peptides.    
 
 
Scheme 1.6 Example of a Strecker reaction performed by Sigman and Jacobsen.50 
 
While these studies as a whole didn’t consecrate organocatalysis as an effective field of 
research, these early examples provided inspiration for many of the reactivity principles in 
common usage today and allowed to understand, for the first time, the role of these small 
organic molecules in the synthesis of very important chiral compounds.18 Only after the 
independent publication of two papers in 2000, as previously mentioned, the potential of 
organocatalysis was recognized, firmly establishing it as an indispensable branch of 
contemporary synthetic chemistry.  Mirroring the enamine reactivity of type I aldolases, 
Carlos Barbas III, Richard Lerner and Benjamin List17 reported that direct asymmetric aldol 
reactions between acetone and simple aldehydes could by catalyzed by L-proline 10 
(Scheme 1.7). This observation occurred during the reinvestigation of the Hajos-Parrish-
Eder-Sauer-Wiechert reaction during the late 1990s – that extended this reaction to several 
others aldehydes in intermolecular aldol reactions – which also opened an avenue for a 
number of related transformations such as the enantioselective intramolecular crossed-aldol 
reaction, as well as Mannich, Michael and Diels-Alder type transformations, and the 
application of these transformations in multistep (domino) reactions.5,52,53  
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Scheme 1.7 Example of an intermolecular aldol reaction studied by Barbas III.17 
 
Simultaneously, Ahrendt, Borths and MacMillan16 reported the first highly 
enantioselective organocatalytic Diels-Alder reaction mediated by an imidazolidinone 13 
derived from L-phenylanine (Scheme 1.8). In that same publication MacMillan defined and 
conceptualized organocatalysis as a new and in expansion branch of asymmetric synthesis. 
Since then, there has been an almost exponential and unprecedented increase in 
publications, citations and research groups working in this field.18  
 
 
Scheme 1.8 Example of a Diels-Alder reaction performed by MacMillan.16 
 
The very good results obtained along the years motivated scientists to study and develop 
new classes of organocatalysts from different chemical structures, such as cinchona 
alkaloids,54 BINOL,55 TADDOL,56 sugars,57 L-proline,58 DMAP59 derivatives, amongst many 
other examples.60-61 However scientist didn’t just focus their efforts on the synthesis of 
catalysts, but also their application. Within a relatively short time frame, modern 
organocatalysis has found application in all branches of synthesis ranging from preparation 
of biologically important compounds to materials science. All the knowledge obtained about 
organocatalysts also permitted the development of new reactions such as tandem, cascade, 
domino and multicomponent reactions,72 as well as reactions in aqueous medium and the 
immobilization of catalysts in solid supports.20,68  
Currently, as mentioned before, there are numerous asymmetric reactions that can be 
catalyzed by organocatalysts,18 such as, for example, halogenations, aldol condensations, 
epoxidations, reductions, Mannich reactions, oxidations, Michael additions, alkylation, 
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arylation, alylation, acylation, Diels-Alder reactions, 1,3-dipolar cycloadditions, amongst 
many others.62 
 
 
1.1.3 Conceptualization 
 
To date organocatalysis has definitively been recognized as the third methodology 
available in asymmetric catalysis, parallel to organometallic catalysis and to biocatalysis (i.e. 
enzymatic catalysis).63 Each of these methodologies possess advantages and 
disadvantages – some of them already mentioned – with some similarities and differences 
between them. The biggest, and maybe most obvious, similarity is that the catalysts used in 
all these methodologies can by principle promote chemical transformations. However, this 
leads us to the main difference between them – the mode of action by which the catalyst 
promotes the chemical reactions. While an organometallic catalyst possesses a transition 
metal as catalytic center, an organocatalyst possess a carbon structure with particular 
heteroatoms endowing it with properties characteristic of a catalytic center. In the case of 
enzymes it’s a little more complicated, because even though they possess hundreds of 
amino acids in their structure, only a small fraction of them belong to the catalytic center and 
they have different properties.64 
In order to establish organocatalysis as the superior methodology of asymmetric 
synthesis, it is important to know the strengths and weakness of all the methodologies 
available. Starting with organometallic catalysis, which for many decades dominated the 
field of asymmetric catalytic synthesis, its main advantage relies on the possibility of using 
different transition metals, increasing ligand structure and subsequently maximizing yields 
and enantioselectivity. This can be done using very small amounts of catalysts (usually 
between 1 to 100 ppm), another significant benefit to this methodology.65 The significant 
disadvantages are mostly related to the high cost of the metal, the fact that the majority of 
metal catalysts are very instable to oxygen and moisture in the atmosphere, and also with 
some problems associated with purification processes.66 Another disadvantage is the low 
amount of metal contamination allowed in pharmaceutical products, which diminishes the 
potential use of this methodology in the pharmaceutical and biological industrys.67  
In regards to biocatalysis, enzymes usually exhibit exceedingly high enantioselectivity 
values due to their complex protein structure. Like in the case of metal catalysts, only a very 
small amount of enzyme catalyst is used and, unlike metal catalysts, they obviously do not 
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present any toxicity issues. However, the presence of organic solvents, temperature and/or 
substrate concentration can inhibit or even denature the enzymes. Besides, it’s usually very 
difficult to synthesize both target enantiomers with these biomolecules, since enzymes can 
only work within a very limited range of structures, due to their characteristic high 
specificity.69 
With the benefits of organocatalysis – previously mention in section 1.1.1 – in mind and 
everything that was formerly said about the other two available methodologies of asymmetric 
synthesis, we can clearly see the advantages of organic molecules as catalysts. The 
weakness of organometallic catalysis and biocatalysis are the strengths of organocatalysis 
– operational simplicity, generally stable under aerobic conditions (i.e. stable when oxygen 
and moisture is present in the atmosphere), and are readily available with very low costs.70 
It is noteworthy that organocatalysis presents some similarities with the other two 
methodologies.  Like for organometallic catalysis, in organocatalysis is relatively easy to 
obtain both enantiomers of a catalytic product.71 In addition, similarly to enzyme catalysts, 
there are no toxicity problems with organocatalysts since they do not possess any metal in 
their structure. Moreover, there is no risk of metal leakage, and no expensive recovery 
process is required for waste treatment. To date the only disadvantage of organocatalysis 
is the amount of catalyst needed in the asymmetric reaction (usually between 1-20 mol%).18 
Table 1.1 summarizes the strengths and weakness of each of the three methodologies 
available in asymmetric synthesis.18  
 
Table 1.1 General summary of the advantages and disadvantages of the three asymmetric 
catalysis methodologies.18 
Characteristic properties Organometallic catalysis Enzymatic catalysis  Organocatalysis 
High catalytic activity       
Wide range of substrates       
Structural simplicity      [a] 
Obtain both enantiomers       
Reduced costs       
Absence of toxicity.        
Oxygen stability       
Aqueous media stability       
Thermic stability       
Organic solvents stability       
Reduced amounts of catalysts       
[a] except for some rare exceptions of organocatalysts with complex structures. 
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Some critics suggest that low turnover numbers (TON), more specifically low turnover 
frequency (TOF), might limit the potential uses of organocatalysis for industrial applications, 
however this point of view is simplistic and dogmatic. From another perspective, cost and 
safety are the most salient considerations for any large-scale catalytic process. Since 
organocatalysts are often cheaper than transition metal-based catalyst, these catalysts can 
be used in larger quantities than metal-based ones for the same price and there is no 
impurities in the final product due to trace metal contamination. Moreover, in manufacturing 
it is widely recognized that the removal of toxic catalyst-related impurities from the waste 
stream can often have a larger financial impact than the turnover number of the catalyst. 
Organocatalysts are more easily removed from waste streams and can be tolerated to a 
large extend in waste streams.18  
Organocatalyst were and still are being studied and develop for the use in potential 
industrial applications. One of the most promising applications is in medicinal chemistry, 
since chiral organocatalysts meet all the operational requirements for the manufacturing of 
therapeutic agents enriched in one particular enantiomer. 1 
 
 
1.1.4 Classification of Modern Organocatalysis  
 
Perhaps most crucial to the success of organocatalysis during the last decades has been 
the invention or identification of generic modes of catalysts activation, induction and 
reactivity. A generic activation mode (or activation mechanism) describes a reactive species 
that can participate in many reaction types with consistently high enantioselectivity. Such 
reactive species arise from the interaction of a single chiral catalysts with a basic functional 
group in a highly organized and predictable manner.18   
The discovery of these modes of activation for organocatalytic transformations basically 
allowed authors to create a general and universal classification of catalysts used in 
organocatalysis. The value of generic activation modes is that, after they have been 
established, it is relatively straightforward to use them as a platform for designing new 
enantioselective reactions.73,74  
In order to better understand the field of organocatalysis, the main activation modes are 
very briefly summarized below and can crudely be divided into covalent and non-covalent 
catalysis, accordingly to the substrate activation. 
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1.1.4.1 Covalent catalysis  
 
The first class of catalysts is the one whose substrate activation occurs trough the 
formation of a covalent bond between the organocatalyst and the substrate, therefore 
increasing the interaction between both of them during the reaction.  Most of the 
organocatalytic reactions occurs trough this type of catalysis, which possess two main 
subcategories – amine catalysis and Lewis base catalysis (or nucleophilic catalysis) (Figure 
1.1).9,73-75 
 
 
Figure 1.1 General activation mode observed in covalent catalysis and its subcategories (catalyst 
structure in blue). 
 
Alkaloids, amino acids, peptides and nitrogen-based synthetic molecules are some of the 
examples of structures that usually belong to this class of organocatalysis, because they 
establish activation covalent bonds with the substrates.9,73-75 
 
 
1.1.4.1.1 Amine catalysis 
 
In the last few years, amine catalysis – catalysis mediated by nucleophilic amines – has 
stood as the center of attentions, being the target of researchers from around the world from 
a synthetic and mechanistic point of view.75  
Taking into account all the knowledge obtained on this subject, amine catalysis earned 
its own particular classification. Initially there were only two known activation modes – 
enamine catalysis17 and iminium catalysis16 – which have become the pillars of 
organocatalysts activation. These two activation modes were expanded to include an 
extension of enamine catalysis (dienamine76 and trienamine77 catalysis) and a new, more 
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recent mode of activation – SOMO78,79 (Singly Occupied Molecular Orbital) catalysis that is 
characterized by the formation of a cationic enamine radical.   
These three modes of activation have distinct reactive intermediaries, however they are 
mechanistically intertwined, and have the reversible condensation between the amine 
function (primary or secondary) of the catalysts and the carbonyl of the substrate as a 
starting point, where an iminium ion is formed (Scheme 1.9).80  
 
 
Scheme 1.9 General formation of iminium ion though reversible condensation between a 
secondary amine and a ketone. 
 
The reaction will occur according to enamine catalysis, iminium catalysis or SOMO 
activation of the substrate depending on the nature of the carbonyl compound (saturated or 
unsaturated) and the surrounding reaction system.  
 
 
1.1.4.1.2 Lewis base catalysis  
 
The other class of organocatalysis that revolves around the formation of a covalent bond 
for substrate activation is Lewis base catalysis (or nucleophilic catalysis).  Generally, the 
catalysts that are included in this class present the common characteristic of possessing an 
atom with severe nucleophilic character in their structure, such as nitrogen, phosphorus and 
sulfur atoms or even a carbon that covalently bonds to the respective substrate.5 There are 
several examples of nucleophilic heteroatoms in the literature, but perhaps one of the most 
interesting is the carbene functionalized organocatalysts, since they are based on enzymatic 
models. N-Heterocyclic carbenes (NHCs) bring an additional level of diversity to nucleophilic 
organocatalysis on account of their structural resemblance and reactivity similarities to the 
coenzyme thiamine (vitamin B1).151 Reactions mediated by NHCs are characterized by the 
presence of an acyl anion intermediate equivalent, more commonly known as the Breslow 
intermediate (Scheme 1.10).82 
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Scheme 1.10 General organocatalytic cycle of a carbene reagent in nucleophilic catalysis. 
 
There are several reported examples of applications of this type of catalyst83, from which 
we highlight the asymmetric Stetter reaction, that can be used to synthesize amino acid 
derivatives.84  
 
 
1.1.4.2 Non-covalent catalysis   
 
The second class of catalyst are the ones whose activation mode occurs trough non-
covalent (weak) bonds between the catalyst and substrate and can by divided into hydrogen 
bonding catalysis, phase transfer catalysis and Brønsted acids or bases (Figure 1.2).9,73,74 
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Figure 1.2 General activation mode observed in non-covalent catalysis and its subcategories 
(catalyst structure in blue). 
 
 
1.1.4.2.1 Hydrogen bonding catalysis  
 
Hydrogen bonds are responsible for many of the structures that surround us. Besides 
there key role in several life depending structures, hydrogen bonds play a crucial role in 
asymmetric catalysis. The activation mode observed in this type of catalysts is based on an 
electronic density decrease of the electrophiles, due to the interaction between the 
organocatalysts hydrogen bonds with this species that activates the organocatalysts 
allowing a nucleophilic attack. In this case, the reaction enantioselectivity is due to the 
immensely organized and weak non-covalent interactions between the nucleophile, catalyst 
and electrophile.85  
This type of organocatalyst is very frequently used, being applied in several catalytic 
applications, such as for example Pictet-Spengler, Mannich, Strecker and Biginelli 
asymmetric reactions and asymmetric reductive aminations.86 
 
 
1.1.4.2.2 Brønsted-Lowry acids and bases 
 
Brønsted acids and bases are an exceptionally important group of organocatalysts in the 
non-covalent catalysis class, due to their many catalytic applications as well as to the 
exceptional results obtained in asymmetric synthesis.   
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In the reactions with Brønsted bases, the nucleophile is formed in situ by deprotonation 
of its precursor and the reaction enantioselectivity is due mainly to the ionic interaction 
between the catalyst and the substrate. The catalysts belonging to this class usually possess 
nitrogen-containing functional groups, such as tertiary amines, guanidine or imidazole. 
Cinchona alkaloids are probably some of the most important catalysts belonging to this 
subclass.88 In the literature there are numerous examples of applications of this subclass of 
catalysts, from which we can highlight the (aza)Henry, Mannich and (hetero)Michael 
reactions as well as kinetic resolution systems89 and some enantioselective rearrangements 
such as Komblum-DeLaMare rearrangements.90  
In this subclass of catalysts we also have Brønsted acids, whose activation, similar to 
catalysis with Brønsted bases, occurs due to the strong ionic interaction resulting from 
substrate (of basic character) protonation by the organocatalysts and formation of a tight 
ion-pair. Once again, this ionic interaction is essential for the enantioselectivity of this 
organocatalyst subclass.87  
  
 
1.1.4.2.3 Phase transfer catalysis 
 
The last discussed type of non-covalent catalysis is phase transfer catalysis, in which 
chiral organic salts are used for the enantioselective preparation of organic compounds. 
Generally speaking, the activation mode of this type of catalysts is based on ionic pair 
interactions between the nucleophilic anion and the positively charged catalysts, usually a 
quaternary ammonium salt.91,92 The general mechanism of phase transfer catalysis (Figure 
1.3) starts with the exchange of the catalyst counter-anion with the nucleophile (cyanide ion 
in the example below) in the aqueous phase. After this exchange, the nucleophile is 
transferred to the organic phase, as part of a tight ion-pair with the organocatalyst, which 
then reacts in the presence of the electrophile.93  
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Figure 1.3 Illustration of the general mechanism of a phase transfer catalysis. 
 
In phase transfer catalysis, the product enantioselectivity is the result of a stereochemical 
control of the chiral catalysts though electrostatic interactions between the catalyst and 
substrate, hydrogen bonds or in some cases π-π interactions.93  
The number of phase transfer catalysts has increased exponentially during the last 
decades, allowing the study and development of several asymmetric catalytic reactions, 
such as aldol reactions, epoxidations, redox reactions, asymmetric alkylation, Michael, 
Strecker and Mannich reactions.93-97 
 
 
1.1.5 Privileged Catalysts 
 
Some catalysts may have the extraordinary capacity to mediate efficiently not only one 
but rather a variety of seemingly unrelated chemical transformations – these are called 
privileged catalysts. The term “privileged” chiral catalyst was coined in analogy to 
pharmaceutical compound classes that are active against a number of different biological 
targets.98 This adjective was conceived to describe some catalyst classes due to their unique 
and highly versatile structure that allows them to be used in several asymmetric applications.  
To date, there is a steadily growing number of such organic compounds, of natural or 
synthetic nature, that possess this incredible chemical property. The list of organocatalysts 
belonging to this category is too extensive to be referenced here in its totality. However, 
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there are some families of this type of structures that deserve to at least be mentioned here. 
The most regularly used organocatalysts are derivatives of L-proline 10, BINOL 14, TADDOL 
15, carbohydrates 16 and cinchona alkaloids 5 (Figure 1.4).9,99 Each family has a different 
historical past and, most importantly, different chemical properties. However, due to the 
nature of the work developed in this dissertation, we will only discuss cinchona alkaloids.  
 
 
Figure 1.4 Examples of carbonated chiral skeletons with privileged catalysts that are used in 
asymmetric catalysis. 
 
 
1.1.5.1 Cinchona alkaloids 
 
Cinchona alkaloids are well-known natural products with a fascinating medicinal history 
and an intriguing molecular structure that is responsible for their use in chemistry.98 The 
readily available and inexpensive cinchona alkaloids are obtained from the bark extract of 
the Cinchona tree, belonging to the Rubiáces family which are native to South America. 
Currently, they are extracted mainly from the bark of Cinchona ledgeriana and consist of 
about 30 alkaloids in total, from which quinine, quinidine, cinchonidine and cinchonine 
represent 50% of these extracted alkaloids.100  
About 50 years ago, interest in these alkaloids arose from a catalytic perspective, and 
consequently these molecules have been historical connected with organic and 
pharmaceutical chemistry, being very important to the welfare of humanity.101 Their history 
goes back to the XVIIth century when the Cinchona bark was used for medicinal purposes 
in Europe – after the discovery of its anti-malaria properties circa 1640. At the time South 
American natives already used the Cinchona barks to treat fevers demonstrating their 
antipyretic properties. As a curiosity, the term “cinchona” was implemented in 1742 by the 
Swedish botanist Linnaeus, after the bark was allegedly used to cure Countess Cinchon, 
the Spanish vice-king of Peru’s wife, from malaria.102 
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Due to its very important medicinal properties, attentions then turned to the discovery and 
isolation of the cinchona alkaloids. The first contribution to the isolation of these natural 
compounds came from the Portuguese naval doctor Bernardino António Gomes in 1811, 
after he performed a then very sophisticated recrystallization of the aldol extract of Cinchona 
bark. Gomes added water and a small amount of potassium hydroxide to the extract 
observing the formation of crude organic product crystals, which he called “cinchonine”.102 
However, Pelletier and Caventou in 1820 showed that the isolated cinchonine by Gomes 
was in fact a mixture of two alkaloids, which they later called quinine and cinchonine.103,104 
A few years later the remaining two alkaloids were isolated – Delondre and Henry105,106 
isolated quinidine in 1833 and Winckler107 isolated cinchonidine (whose name was given by 
Pasteur in 1851) in 1847.  
700 tons of cinchona alkaloids are obtained annually due to their several applications and 
their industrial importance. For example, 40% of the extracted quinine is used in the 
pharmaceutical industry, and the remaining 60% is used in the food industry manly as bitter 
aromatic agents in tonic and other soft drinks.108 Quinidine is already used in the medicinal 
industry as an antiarrhythmic drug and cinchonidine is used in the racemic resolution of 
naproxeno.109   
Interest in the field of asymmetric catalysis with cinchona alkaloids has increased 
tremendously in the last two decades as part of the sudden explosion of interest in 
organocatalysis. Preceding the present interest in cinchona alkaloids, their use in 
asymmetric synthesis has been extensively reviewed and compiled by several authors, such 
as Pracejus110 in 1967, Morrison and Mosher111 in 1971, Wynberg112 in 1986, Kacprazak e 
Gowroński113 in 2001, Kaufman e Rúveda102 in 2005, Marcelli and Hiemstra54 in 2010, Xi 
and Shi114 in 2013 and most recently Zheng and Shienebeck115 in 2014, as well as Song’s 
book100 in 2009 and many others.9,116-118  Briefly, the earliest examples of the use of cinchona 
alkaloids in catalysis are the addition of HCN to benzaldehyde as reported by Bredig and 
Fiske36 in 1912 (Scheme 1.2), the work of Pracejus37,38 in 1960 on the addition of methanol 
to phenyl methyl ketene (Scheme 1.3) and the pioneering work by Wynberg and 
coworkers112, who showed that cinchona alkaloids can serve as catalysts for various 
enantioselective reactions. Until the late 1990s, cinchona alkaloids and its derivatives were 
mainly applied in phase transfer catalysis.119-121,154 Succeeding these early studies, 
numerous reports have appeared concerning organocatalysis with cinchona alkaloids and 
synthetically prepared derivatives thereof.  
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So what makes Cinchona alkaloids effective and attractive as catalysts? They fulfill all 
the requirements usually associated with privileged catalysts – they are commercially 
available compounds, of low cost due to high production, are stable and recoverable 
compounds, as well as of robust and versatile structure which allows them to be easily 
modified for diverse catalytic applications. This makes cinchona alkaloids a target of 
interests from the scientific community.113  
In terms of asymmetric catalysis, the cinchona alkaloid family consists of two pairs of 
diastereomers – cinchonine (CN)/ cinchonidine (CD) and quinine (QN)/ quinidine (QD) 
(Figure 1.5).113 Their unusual and rich structure is the key that makes these four alkaloids of 
extreme importance in several areas, particularly in (organo)catalysis.  
 
 
Figure 1.5 Chemical structure of the two diastereomeric pairs of Cinchona alkaloids and their 
respective chiral center absolute configuration. 
 
The elucidation of the complete structure of these alkaloids was not an easy one, having 
taken longer than 50 years to conclude. The atomic numbering that is currently used in 
cinchona alkaloids was initially proposed by Rabe in 1907 – a German chemists that 
dedicated more than 40 years of his life to the study of quinine.122,123 However, only in 1944 
did this stereochemical assignment, as it is currently known, was completed by Prelog and 
Zalan.124,125  
The natural cinchona alkaloids possess several functional groups that can be divided in 
four different parts – the quinuclidine moiety (a bicyclic tertiary amine), a quinoline part 
(aromatic ring), a secondary alcohol (or a β-hydroxylamine subunit) and a vinyl or ethyl 
group connected to the quinuclidine unit.   
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Both diastereomeric pairs have five stereogenic centers in their structure, four of them 
chiral carbons (C3, C4, C8 and C9) and one chiral nitrogen of quinuclidine (N1).54,98 The 
absolute configuration in N1, C3 and C4 is the same in all cinchona alkaloids, with the 
absolute configuration only differing in C8 and C9.126 When employed in asymmetric 
catalytic reactions, each pair of these catalysts is responsible for the enantioselective 
product with the opposite absolute configuration (i.e. quinine and cinchonidine are (-) and 
thereby induce selectivity for one enantiomer, while quinidine and cinchonidine are (+) and 
afford the other enantiomer), acting as enantiomeric pairs. Thus despite CD/CN and QD/QN 
being chemically diastereomers (i.e. there not mirror image of each other and not 
superimposable), they act as enantiomers with asymmetric catalytic power, known as 
pseudo-enantiomers. In other words, if CD/CN and QD/QN didn’t possess the vinyl group 
connected to the quinuclidine unit, they would be enantiomers.54,98,113,127,128  
Because of the presence of the secondary alcohol (Lewis acid site) and the nitrogen in 
the quinuclidine unit (Brønsted base site), cinchona alkaloids and their derivatives are 
bifunctional catalysts. Cinchona alkaloids are mechanistically characterized as Brønsted 
bases when the nitrogen moiety partially or fully activates a proton, resulting in the chiral 
intermediate species with facial selectivity in asymmetric catalysis.129  
Cinchona alkaloids can adopt different conformations due to the rotations about the C4’-
C9 and C9-C8 bonds. Through both NMR spectroscopy and computational techniques, four 
low-energy conformers called anti-closed, syn-closed, anti-open and syn-open were 
identified (Scheme 1.11). This denomination comes from the fact that in the “open” 
conformers, the quinuclidine nitrogen is distant from the quinoline, being “exposed”, while in 
“closed” conformers the same nitrogen is aligned with the quinoline, “blocking” it. The syn 
and anti is related to the position of the hydroxyl in relation to C6’ hydrogen: syn when both 
are on the same side and anti when they are on opposite sides.126, 130-134  
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Scheme 1.11 The four principal conformers of quinidine.126 
 
According to molecular modeling (MM) calculations, quinine and quinidine preferentially 
adopt the syn-closed conformation in the gas phase. However, in apolar solvents the anti-
open conformation is preferred, whereas polar solvents favor the two closed conformers, 
syn-closed and anti-closed. In addition, protonation of the quinuclidine nitrogen atom is 
reported to hinder rotation about C4’-C9 and C8-C9 bonds. In the case of cinchonidine, NMR 
studies and MM calculations showed that anti-open conformation is preferred when 
protonated. This shows that many factors (such as nature of solvent, intermolecular 
interactions, protonation) can influence the complex conformational behavior of cinchona 
alkaloids in solution.135,136   
One should note that substituents at C9 play a key role in determining the conformation 
of cinchona alkaloids. For example, esters are present in the anti-closed form in solution, 
while C9 methyl ethers prefer anti-open conformation.137 
As previously mentioned, cinchona alkaloids have a versatile structure that allows simple 
and selective derivations in different key places of these molecules. These derivations allow 
maximization of the catalytic activity for several asymmetric applications.  
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There is “no limits” to the possible derivations that can be carried out on cinchona 
alkaloids, however most derivatizations are in the C9 secondary alcohol position, the 
quinuclidine nitrogen and the quinoline methoxyl (in the case of quinine and quinidine).113 
The most common derivations that can be done with these catalyst are the following. In the 
case of the secondary alcohol in C9 (which in its native form acts as weak acid as well as 
hydrogen bond donor), this can be easily derived or substituted by other groups, creating 
new functional groups such as amides, thioureas, ethers, esters, free or substituted amines, 
guanidine, amongst many others. Many of these transformations lead to a configuration 
inversion of C9, forming what it is known as epi-alkaloids. The quinuclidine nitrogen also has 
a very important role because it can be easily alkylated forming quaternary ammonium salts, 
widely used in phase transfer catalysis. In the case of quinidine and quinine, the methoxyl 
group present in the quinoline unit can be, for example, substituted by a hydroxyl group or 
even an amine, which can be further derivatized.99 
Lastly, but definitely not least, the vinyl group connected to the quinuclidine allows the 
catalyst to be immobilized on different solid supports. This transformation allows the 
catalyst’s recovery and recycle after a catalytic reaction, granting economic advantages, 
especially on an industrial scale.138  
Due to the work developed during this dissertation, from the several functionalization that 
can be done in the alkaloids we have special interests in the pyridinecarboxamides derived 
cinchona alkaloids (i.e. substitution of C9 alcohol by a picolinamide group) and will discuss 
it in more detail in section 1.1.5.1.1. 
 
Cinchona alkaloids have successfully and efficiently been employed in a number of 
chemical and medicinal applications. One of the most important applications is perhaps their 
use in organocatalytic asymmetric transformations. As previously mentioned, the use of 
cinchona alkaloids in asymmetric synthesis is not something new (dating back to the 1900s), 
however, only recently some very good results have been reported. Wynberd and 
collaborators – who used these natural compounds as nucleophilic catalysts – demonstrated 
that cinchona alkaloids are very versatile and can be applied in a wide range of reactions. 
In 1981, Wynberg and Hiemstra139 reported that cinchonidine (CD) is a very good catalyst 
in the conjugated addition of aromatic thiols to α,β-unsaturated cyclohexanones (Scheme 
1.12), while somewhat lower e.e.’s were obtained with quinine and quinidine. 
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Scheme 1.12 Asymmetric conjugated addition using cinchonidine as catalyst reported by Wynberg 
and Hiemstra.139 
 
Later, Wynberg reported the synthesis of β-lactones (intermediaries in malic acid 
synthesis), using quinine as organocatalyst. The reaction between ketenes and chloral 
afforded the desired products with an impressive enantioselectivity of 98% and with equally 
good yields.140  
Another very important development in the use of cinchona alkaloids appeared in 1995 
when Brunner141 reported the synthesis of 9-amino-(9-desoxy)-epi-cinchona derivatives. 
After the turn of the millennium, in 2007, the enantioselective catalytic potential of these 
molecules were revealed when Cheng and Deng142 reported their use in Michael additions 
and when Melchiorre143 used them in Friedel-Crafts alkylation reactions (Scheme 1.13), both 
with very good yields and enantioselectivities.  
 
Scheme 1.13 Friedel-Crafts alkylation reported by Melchiorre.143 
 
During the next few years the cinchona alkaloid derivatives were used in numerous 
catalytic reactions, such as rearrangements, epoxidations, Diels-Alder, substitution and aza-
Michael reactions.144-153 
The dawn of the “golden age”155 of organocatalysis led to the development of this field as 
a whole and brought with it innovation, creativity and enthusiasm for the study and 
development of new classes of relatively simple, low cost, effective and versatile cinchona 
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alkaloids, in order to obtain enantiomerically pure products as well as develop new catalytic 
reactions (Scheme 1.14).157-170  
 
 
Scheme 1.14 Asymmetric organocatalytic Wittig [2,3]-rearrangement of oxindole catalyzed by a 
squaramide derived cinchona alkaloid reported by Ošeka165 in 2016. 
 
Inevitably the industry became interested in organocatalysts (which will be briefly 
discussed in section 1.1.6).  
 
 
1.1.5.1.1 Pyridinecarboxamides derived cinchona alkaloids 
 
In the past decade, picolinamides – amides derived from commercially available picolinic 
acid – have been successfully incorporated as functional subunits in several carbon 
skeletons of organocatalysts. These new type of skeletons have demonstrated some very 
good and promising results, regarding asymmetric organocatalysis. One example is the 
work reported by Wang171 in 2012. They reported an asymmetric Biginelli reaction with good 
yields and excellent enantioselectivity, using the bifunctional organocatalyst 20 composed 
of a primary amine and a picolinamide subunit (Scheme 1.15). 
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Scheme 1.15 Enantioselective Bignelli reaction catalyzed by an organocatalysts containing a  
picolinamide subunit (represented in blue) reported by Wang.171 
 
Another example is the work performed by Zhang172 in 2007 on the development and 
application of chiral N-picolino amino alcohols in ketimine reduction using trichlorosilane as 
a reducing agent (Scheme 1.16). 
 
 
Scheme 1.16 General representation of Zhang’s work in the asymmetric reduction of ketimines.172 
 
The incorporation of picolinic acid in a chiral compound led, once again, to very good 
results. There are many other examples in the literature such as that reported by 
Matsumura173, Benaglia174-176 and Jones.177 
Inspired by these very good results, Barrulas and Burke178 developed a new class of 
cinchona alkaloids – cinchona-derived picolinamides179. This new class of organocatalysts 
was then applied in the stereoselective hydrosilylation of imines (Scheme 1.17), affording 
very good yields and enantioselectivities.180  
+ 
2 0 
C a t . 
  2 0 
( 1 0 m o l % ) 
H C l 
  ( 1 0   m o l % ) 
1 , 4 - d i o x a n e / C H C l 3 
( 8 : 2 ) 
H 2 N N H 2 O E t 
O 
O O O 
+ 
N H 
H N 
C O 2 E t 
O 
( e . e . > 9 9 % ) 
H 2 N H N 
O 
N 
Introduction 
 
 
33 
 
Scheme 1.17 Enantioselective reduction of ketimines using a cinchona-derived picolinamide as 
organocatalyst reported by Barrulas.180 
 
Motivated by these very good results, we decided to apply these picolinamides derived 
from cinchona alkaloids in the stereoselective reduction of ketimines, more specifically 
ketimines intermediates of Rivastigmine and other biologically active compounds (this topic 
will be discussed in section 1.2). To the best of our knowledge there are no further reports 
of the use of cinchona-derived picolinamides in any other synthetic applications.  
 
 
1.1.6 Industrial and Medicinal Chemistry Applications of Organocatalysis 
 
Due to the establishment of organocatalysis as an effective field of research, this area 
has aroused a lot of attention from the pharmaceutical industry. However, the expansion 
and development of catalytic process that can be applied at the industrial scale is an arduous 
one, because industries focus mainly on profit generation.  
In the last few years, pharmaceutical interest in organocatalysis has increased mainly 
due to its, previously referred, benefits over organometallic catalysis and the very expensive 
biocatalysis. The scale-up of organocatalysis has some inherent problems, such as catalyst 
loading for the process, product inhibition, substrate range and catalysts efficiency for 
specify reactions.65 The chemical and pharmaceutical industry as well as academia has 
been working on surpassing these obstacles and are currently taking steps towards 
establishing organocatalysis as an effective alternative to current methodologies on the 
industrial scale. 
In order to highlight the role of organocatalysis in industrial applications we will present 
some key examples available in the literature. One example is the use of an organocatalyst 
in the synthesis of antimalarial agents. Currently, only a small number of safe drugs for the 
treatment of malaria exists, one of them being tetrahydropyridine (THP). A small library of 
these TPH was recently synthesized in a one-pot reaction using L-proline/TFA as 
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organocatalyst and with low cost starting materials (Scheme 1.18). Preliminary in vitro 
studies showed very promising results for the antimalarial activity of these compounds.181  
 
 
Scheme 1.18 Tetrahydropyridines synthesized and tested as possible antimalarial agents in 2009 
by Tripathi and coworkers.181 
 
Another example is the synthesis of compounds with anti-HIV activity using 
organocatalysts. There are several studies on this subject but we would like to point out the 
one performed by Ma and his team182 in 2013. They developed a decarboxylative 
asymmetric Mannich reaction between β-keto acids and ketimines using a monosaccharide-
derived amino thiourea 23 as organocatalyst (Scheme 1.19). There were able to obtain the 
desired product with an astounding 99% yield and enantioselectivity of 99%. This study 
revealed to be a new and efficient pathway to asymmetrically synthesize the anti-HIV drug, 
DPC 083.182 
 
 
Scheme 1.19 Synthesis of intermediates for the preparation of anti-HIV compounds by Ma.182 
 
In 2009, Koskinen and his team183 described a new enantioselective synthesis of an anti-
convulsive and anti-epileptic drug – pregabalin, commercially sold by Pfizer as Lyrica® – 
used for the treatment of epilepsy and neuropathic pain. They used a quinidine derived 
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thiourea 24 in an asymmetric Michael addition of Meldrum’s acid to a nitro-olefin – a key 
step in the synthesis of this drug – with good yield and an ee of 75 % (Scheme 1.20).183 
 
Scheme 1.20 Enantioselective synthesis of Pregabalin developed by Koskinen and his team.183 
 
One last example is the work developed by Wang and collaborators184 in 2011. Wang 
reported that cinchona alkaloid derivatives, more specifically derived from quinine, are 
extremely efficient catalysts when applied to asymmetric aza-Mannich additions of N-tosyl 
imines, with good yields and an e.e. of up to 99% (Scheme 1.21). The products obtained by 
this reaction showed anti-cancer activities.184 
 
Scheme 1.21 Wang’s work developed in 2011 for anti-cancer applications.184 
 
In the literature there are many other applications of organocatalysis for (at least in part 
of) the synthesis of compounds with medicinal interests. The use of organic catalysts in the 
total synthesis of some well-known drugs have been reported, such as Oseltamivir185 
(commercial sold by Roche as Tamiflu®), Paroxetine186 (an antidepressant), Maraviroc187 
(an anti-viral), Blacofeno188 (a muscular relaxant) and Warfarin189 (an anticoagulant).   
The results obtained in this dissertation work can also be considered another example of 
the application of organocatalysis in medicinal chemistry, since we have applied 
organocatalysts (more specifically picolinamides derived from cinchona alkaloids) in the 
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synthesis of Rivastigmine, a drug used for the treatment of Alzheimer’s disease (see section 
1.2).   
 
 
1.2 Rivastigmine  
 
1.2.1 General Aspects 
 
Rivastigmine (Figure 1.6) – (S)-N-ethyl-3-[1-(dimethyl-amino)ethyl]-N-methylphenyl 
carbamate – is a noncompetitive, reversible acetylcholinesterase (AChE) inhibitor used in 
the treatment of mild to moderate dementia associated with Alzheimer’s disease (AD) and 
in some cases with Parkinson’s disease (PD). It is referred to as a pseudo-irreversible 
inhibitor because it is considered a long duration reversible inhibitor.190-192  
 
 
Figure 1.6 Chemical structure of (S)-Rivastigmine. 
 
Alzheimer’s disease is an irreversible, complex, neurodegenerative disorder 
characterized by progressive cognitive impairment, a variety of neuropsychiatric and 
behavioral disturbances and restrictions in daily life activities.193 This is an age related 
disease and is the most common cause of dementia in the older population. It’s very rapidly 
becoming a worldwide public health concern, affecting up to 10% of the population over the 
age of 65 and 30% or more of the population over the age of 80. In the developed world, AD 
is the fourth major cause of death, after cardiovascular disease, cancer and cerebral 
accidents. With the increase of life expectancy due to the advances of modern medicine, 
the number of AD patients is anticipated to increase drastically. Worldwide, there are 
approximately 35 million people suffering from AD, and that number is expected to grow to 
107 million by 2050. 194-195 In Portugal is estimated that about 153 000 people suffer from 
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dementia, 90 000 of them suffering from AD. In other words, about 1% of the Portuguese 
population has AD.196  
The etiology of AD is not yet known, however the neuropathological changes typically 
observed in the brain of AD patients is well documented. The postmortem brain examination 
of AD patients has shown that the loss of the basal forebrain cholinergic system is one of 
the most significant aspects of neurodegeneration in the AD suffering brains, and it is 
thought to play a central role in generating cognitive impairments.194 Over the years, several 
therapeutic strategies were studied. Enhancement of cholinergic transmission – increase of 
cholinergic neurotransmission in relevant parts of the brain by the use of acetyl 
cholinesterase (AChE) inhibitors to delay the breakdown of acetylcholine (ACh) released 
into synaptic clefts – has been regarded as one of the most promising methods for treating 
AD patients. Clinical trials have shown that AChE inhibitors are among the best known 
therapeutic drugs for AD treatment.197  
The discovery and development of Rivastigmine (ENA 713) arose from the search for a 
novel AChE inhibitor with enhanced clinical efficacy and improved pharmacokinetic and 
pharmacodynamic properties compared with earlier compounds. In 2006, Rivastigmine 
became the first U.S. FDA and the first worldwide approved drug for the treatment of mild to 
moderate dementia associated with AD.198  
Rivastigmine belongs to the carbamate group of AChE inhibitors and has a distinct 
chemical structure relative to other AChE inhibitors. It’s known as a dual inhibitor because it 
works by blocking AChE, the enzyme responsible for ACh degradation, and 
butylrylcholinesterase (BuChE), the enzyme responsible for the hydrolysis of ACh, thereby 
increasing both the level and duration of the neurotransmitter acetylcholine.199  
In particular, Rivastigmine appears to have marked effects in patients showing a more 
aggressive course of the disease, such as those with early onset AD or those experiencing 
symptoms such as nausea and vomiting. The high potentiality of Rivastigmine against 
Alzheimer’s disease deserves an appropriate position in the “Blockbuster Drug List”.190  
Rivastigmine is commercially sold as Exelon® by Novartis, Switzerland. To the best of 
our knowledge, the methodology used by Novartis for Exelon® synthesis is not publicly 
know. However, by a brief overview of the existing literature, we can see that there are a 
few and well cited synthetic methodologies available for the synthesis of Rivastigmine.191-200 
These methodologies address a wide range of chemical transformations, and to date, 
several asymmetric methods have been developed for the preparation of enantiopure 
Rivastigmine (e.g. racemate resolution using chiral acids201-203, asymmetric addition of 
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organozinc species onto imines using transition metal catalysis,204 diastereoselective 
reductive amination205 or lipase-catalyzed (dynamic) kinetic resolution of a hydroxy-
presursor206-208). Generally speaking, the only successful catalytic route to this class of 
compound is via asymmetric catalytic hydrogenation of ketimines (see 1.2.2.1).  
An asymmetric total synthesis of Rivastigmine was recently reported, and it entailed the 
formation of the chiral amine moiety via enzymatic reductive-amination of the corresponding 
ketone precursor employing ω-transaminases209 (Scheme 1.22). Very good results in terms 
of yield and enantioselectivity were attained. However, some problems were observed, 
namely the reaction equilibrium, which was displaced more on the alanine/ketone side.210 
There are other examples of chemeoenzymatic synthesis of Rivastigmine, for example using 
alcohol dehydrogenase from baker’s yeast211 or ketoreductase212. 
 
 
Scheme 1.22 Chemeoenzymatic asymmetric synthesis of (S)-Rivastigmine reported by Fuchs and 
his team.209 
 
The use of organocatalysts in Rivastigmine synthesis hasn’t been much explored. To the 
best of our knowledge, there is only one publication on the use of organocatalysts in the 
synthesis of this compound, namely Cinchona-derived quaternary ammonium salts for 
stereoselective imine reductions.213 Some very good, preliminary and promising results on 
Rivastigmine synthesis were obtained.  This study was performed in collaboration with the 
Benaglia group, at the Università Degli Studi di Milano, Italy, and our group at Universidade 
de Évora.  
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1.2.2 Target Reaction  
 
1.2.2.1 Reduction of ketimines 
 
Chiral amines are an important class of structural motifs found in a vast array of natural 
products and biologically active compounds, and it is thus imperative to develop synthetic 
methods for the construction of stereogenic centers bearing nitrogen.214 The asymmetric 
reduction of the C=N bond is one of the most straightforward approaches to afford chiral 
amines. There is a wide range of methods for the reduction of imines and carbonyl 
compounds to chiral amines or alcohols, from asymmetric hydrogenation to asymmetric 
hydrosilylation to transfer hydrogenation, using transition metals, enzymes or purely organic 
catalysts.215-217  
The asymmetric hydrogenation of unsaturated organic compounds is currently becoming 
a standard procedure in both academic laboratories and industrial applications. Until 
recently, all the methods developed for the reduction of organic compounds have been 
dominated by the use of metal catalysts coordinated with specific stereodiscriminating chiral 
ligands, however recently this changed due to the discovery that simple small organic 
molecules are able to catalyze chemeoselective reductions.218 The enantioselective 
reduction of imines to obtain chiral amines still represents a challenge. Although many highly 
enantioselective hydrogenations of ketones and alkenes are known, only less effective 
reductions of imines are available. The development of efficient catalysts giving high 
enantioselectivity has proved to be much more difficult in the case of imines, compared with 
alkenes and ketones.1  
The name hydrosilylation (or hydrosilation) refers to the reaction of addition of organic 
and inorganic silicon hydrides to π bonds, in particular carbon-carbon and carbon-
heteroatom (i.e. carbon-oxygen and carbon-nitrogen) double bonds.  The first example of 
hydrosilylation dates back to 69 years ago, when in 1947 Leo Sommer reported the reaction 
occurring between trichlorosilane and 1-octene in the presence of acetyl peroxide.219  
Until a decade ago, while the hydrosilylation of ketones was well established, ketimines 
were scarcely recognized by researchers, with only a limited portfolio of acceptably efficient 
protocols reported at the time.220 In the last few years, the development of new catalysts for 
the asymmetric catalytic reduction of chiral ketimines became the main objective for 
researchers all around the world, due to the well-established importance of chiral amines in 
the pharmaceutical industry.221  
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A variety of reducing reagents have been used for ketimine asymmetric reduction but it 
is still worthwhile to exploit new methods, which can be carried out using inexpensive 
reducing reagents under mild conditions. Compared with the chiral Brønsted acid catalyzed 
asymmetric transfer hydrogenation, in which the electrophile substrate (C=N bond) was 
activated by Brønsted acid via formation of an ion pair or hydrogen bond, Lewis base 
catalyzed hydrosilylation of C=N bond proceeds through a coordination of the Lewis base 
with a silane, which could form a more reactive hypervalent silane complex.1 Silanes are 
very attractive reagents since they are relatively cheap, non-toxic and are considered non-
metal compounds and thus have received considerable attention from organic chemists.225  
Trichlorosilane (HSiCl3) is a colorless liquid, readily available material primarily 
manufactured and used in the organosilicon industry. This reagent accounts for 75% of the 
world’s production of polycrystalline silicon through the Siemens process, in which high 
purity silicon rods are exposed to trichlorosilane at elevated temperatures, leading to 
decomposition of the trichlorosilane and additional silicon to be deposited onto the rods.222 
Thrichlorosilane needs to be activated by coordination with a Lewis base to generate 
hexacordinated hydridosilicate, believed to be the reducing agent that operates under mild 
conditions. The use of chiral Lewis bases223 offers the potential to control the absolute 
stereochemistry of the process, and this has been widely explored in the last decade, leading 
to the development of some very efficient catalysts, such as chiral tertiary amines, 
sulfonamides, amino alcohols, imidazole derivatives, picolinamides and N-formamides.224 
Trichlorosilane has already been employed on large scales for transforming phosphane 
oxides into phosphines and N-acyliminium ions into N-acylamines. Although the 
methodology may present some problems with regards to, for example, the generation of 
some quantities of halogen waste, it undeniably deserves consideration as a viable tool for 
the synthesis of chiral secondary amines.226  
The organocatalytic reduction of ketimines is a relatively recent field of research. The first 
reported example of asymmetric reduction of ketimine using a chiral Lewis base and 
trichlorosilane as the hydride was by Matsumura227 in 2001. The proline-derived chiral 
formamide 26 facilitated the reduction of a variety of N-phenyl and benzyl protected aryl 
methyl ketimines with excellent yield and moderate enantioselectivity of up to 66% (Scheme 
1.23). Although only moderate enantioselectivities were obtained for the chiral amine 
products, this preliminary results opened the door to the chemistry of imine reduction with 
organic Lewis base catalysts. 
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Scheme 1.23 Reduction of aryl methyl ketimines using a proline-derived chiral formamide as 
organocatalyst developed by Matsumura.227 
 
Three years later, Malkov and Kocovsky228 and co-workers developed another type of N-
formyl-based Lewis base derived from L-valine. These types of catalysts are more flexible 
since they are open chain, compared with the proline framework of the previously studied 
catalysts, yet they are highly efficient for the asymmetric reduction and provided up to 92% 
ee. The authors proposed a transition state for their catalysts (Figure 1.7), where it 
coordinates with trichlorosilane to form a hexacoordinated complex, in which hydrogen 
bonding and π-π staking are possibly involved, according to some experiments they 
conducted.228 This study was decisive for the development of new organocatalysts by 
research groups from all around the world.  
 
 
Figure 1.7 Transition state proposed by Malkov228 for the hydrosilylation of ketimines catalyzed by 
L-valine derivatives. 
 
While an N-formyl group was essential for previous chiral activators of thrichlorosilane, 
Kocovsky229 and Matsuda230 independently reported a new non-N-formyl Lewis base 
organocatalysts – based on chiral pyridyl-oxazolines and isoquinolyloxazolines – in 2006. In 
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the following years, there were reported numerous applications in this field.220,221,225,231-235 In 
2013, Benaglia226 et al. reported the enantioselective reduction of ketimines promoted by 
several proline derivatives, with good yields and a highest enantioselectivity of up to 77% 
(Scheme 1.24). 
 
 
Scheme 1.24 Hydrosilylation of ketimines with new L-proline derivatives developed by Benaglia and 
his team.226 
 
In the same year, Wang236 et al. applied N-formamides derived from L-pipecolic acid in 
the hydrosilylation of ketimines, for which they obtained exceptional results (Scheme 1.25). 
 
 
Scheme 1.25 Asymmetric hydrosilylation of ketimines with L-pipecolic acid reported by Wang.236 
 
As previously mentioned, last year, Barrulas180 et al. reported the use of cinchona-derived 
picolinamides – a new type of chiral Lewis base, a cationic species – in the stereoselective 
imine hydrosilylation of a wide range of aromatic ketimines (Scheme 1.17). They obtained 
excellent yields with good to high enantioselectivities (up to 91%) and observed remarkably 
high turnover frequencies for the hydrosilylation of imines.  
The use of organocatalysts in hydrosilylation of ketimines is a new and very promising 
field that’s still in development with new studies being published every year – such is the 
objective of the work developed during this master’s dissertation. However, the main 
challenge is the moderate TOFs and TONs associated with these organocatalytic 
processes, particularly when compared to those obtained from metal-based catalysis.  
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“Nothing has such power to broaden the mind as the ability to investigate systematically 
and truly all that comes under thy observation in life.” 
Marcus Aurelius 
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The main objective of this dissertation project was the synthesis of a pharmaceutically 
active agent, Rivastigmine, using an organocatalytic method. To accomplish this objective, 
we designed a general synthetic pathway were the enantioselective reduction of ketimine 
intermediates (precursors of Rivastigmine), catalyzed by a recently developed family of 
cinchona alkaloids derivatives, was the key step.  
 The results acquired during this project as well as their discussion are divided in four 
distinct sections. First we present the results obtained for the synthesis of the selected 
organocatalysts (namely cinchona-derived picolinamides). Secondly, we discuss the 
synthesis of Rivastigmine precursors, which are divided by the precursor type. And this is 
followed by the application of the synthesized catalysts in the asymmetric reduction of 
ketimine intermediates. Lastly, we present some preliminary results obtained for the 
immobilization of this class of organocatalysts.  
 
 
2.1 Synthesis of 9-Picolinamide-Cinchona Alkaloid Organocatalysts 
 
The synthesis of picolinamides derived from cinchona alkaloids was an important goal of 
this project. These organocatalysts have previously shown high activity and 
enantioselectivity in the hydrosilylation of ketimines,180 which led us to using them in the 
enantioselective reduction of the desired Rivastigmine precursors.  
Before the preparation of the organocatalysts, we had to choose which of the four 
commercially available cinchona alkaloids to start from. Because we wished to obtain only 
one of the Rivastigmine enantiomers – the (S) enantiomer – we choose to work with the (-)-
quinine and cinchonidine, which are known to give the desired enantiomer in the asymmetric 
reduction of ketimines used in this project.180,213 As already mentioned, the complete 
synthesis of cinchona-derived picolinamides has been previously established by Barrulas et 
al.178,179 The synthesis of both the quinine and cinchonidine-derived catalysts was carried 
out using the same experimental protocol.  
Starting from commercially available quinine, first we transformed the hydroxyl present in 
this compound in a mesylate group (Scheme 2.1). This is a well-known chemical reaction 
that comes down to transforming a weak leaving group (hydroxyl) into a very good leaving 
group (mesylate), which is very useful in many nucleophilic substitutions at C9 position and 
mesylates usually can be handled more easily. The mesylation of quinine (and cinchonidine) 
has been previously reported by Hoffmann237 in 2003. We used the same experimental 
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conditions as Hoffmann in the synthesis of quinine-derived mesylate compound 29, with a 
yield of 90% (slightly higher than the 82% obtained by Hofmann238). The mesylation step 
proceeded with complete retention of configuration in the C9 position.    
 
 
Scheme 2.1 Synthetic pathway for 9-amino-(9-deoxi)-epi-quinine 31. Reagents and conditions: a) 
MsCl, NEt3, THF, 0ºC; b) NaN3, DMF, 80-85ºC; c) (1) PPh3, THF, (2) H2O. 
 
The next step in the synthesis of 9-amino-(9-deoxi)-epi-quinine 31, was the preparation 
of azide compound 30. This step is also a classical reaction in organic chemistry, a 
bimolecular nucleophilic substitution (SN2). In this case, a nucleophilic substitution with 
complete inversion of configuration at the electrophilic carbon C9, occurred in the presence 
of an azide nucleophile (N3-). There are several azidation methods described in the literature, 
which differentiate mainly in the azide anion source such as hydrazoic acid, trimethylsilyl 
azide, diphenylphosphoryl azide, sodium azide, amongst many others.239 Due to 
experimental simplicity and for less exposure to dangerous and toxic reagents, we chose a 
method already described for cinchona alkaloid derivatives240, that uses sodium azide as an 
azide anion source. With this method, we were able to obtain the desired quinine compound 
30 with an 89% yield.  
Having successfully prepared the azide compound 30, we set out to obtain the amine 31. 
9-amino-(9-deoxi)-epi-quinine and 9-amino-(9-deoxi)-epi-cinchonidine are a secondary 
amine that has been previously synthesized and applied in several organocatalytic 
asymmetric processes. The first described synthesis of these chiral amines dates back to 
the mid-1990s, when Brunner114 reported it in 1995. Based on the work developed by 
Brunner114 we choose to do the chemeoselective reduction of the azide using a Staudinger 
reaction241 (Scheme 2.2).  With the Staudinger reaction we were able to synthesize 9-amino-
(9-deoxi)-epi-quinine 31 with a very good yield (82%), having a global reaction yield of 66% 
after three steps.  
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Scheme 2.2 Reaction mechanism for the Staudinger reaction performed to obtain amine 31. 
 
For the synthesis of 9-amino-(9-deoxi)-epi-cinchonidine 34 we followed the same 
synthetic pathway as the one previously described for the quinine derivative (Scheme 2.3), 
starting from the commercially available cinchonidine and with a very good global reaction 
yield of 80%.  
 
 
Scheme 2.3 Synthetic pathway for 9-amino-(9-deoxi)-epi-cinchonidine 34. Reagents and 
conditions: a) MsCl, NEt3, THF, 0ºC; b) NaN3, DMF, 80-85ºC; c) (1) PPh3, THF, (2) H2O. 
 
After the successful preparation of the amine compounds 31 and 34, we then focused on 
the synthesis of the target picolinamide derivatives. To achieve this, we needed to complete 
the next reaction step that consisted of the formation of an amide bond. There are numerous 
methods available in the literature to perform this transformation, from a simple direct 
condensation between a carboxyl and an amide at high temperatures242 (in which there is 
the elimination of a water molecule for each amide bond formed), to a catalytic condensation 
with Lewis acids242,243 or through coupling reactions after carboxyl activation.244-247 All the 
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available methods for this transformation, as seen in many other organic chemistry 
methodologies, have their disadvantages, due to many aspects such as, for example, harsh 
reaction conditions or byproduct formation.  
In regard to compound 36, we initially performed its synthesis by a direct condensation 
between the cinchonidine-derived amine 34 and commercially available picolinic acid 35 
(Scheme 2.4). The reaction was carried out in toluene and under reflux, using a Dean-Stark 
apparatus for the removal of released water during the reaction.242 After the purification step, 
we were able to obtain picolinamide-derived catalyst 36 with a yield of 74% and a global 
reaction yield of 59% (after four reaction steps). 
 
 
Scheme 2.4 Synthesis of 9-picolinamide-(9-deoxi)-epi-cinchonidine 36 through a direct 
condensation. 
 
We decided to also use the direct condensation method for the synthesis of the N-methyl 
pyridinium salt derived catalyst 38 (Scheme 2.5).  Before performing the direct 
condensation, we first need to synthesize compound 37 – the N-methyl picolinic acid. There 
are several described methods for the methylation of amines and we decided to use a 
bimolecular nucleophilic substitution with the method developed by Liebscher.248 Through a 
SN2 reaction between the commercially available picolinic acid and iodomethane in iPrOH, 
we were able to obtain the desired compound with a yield of 68%.  
 
 
Scheme 2.5 Synthetic pathway used for the synthesis of compound 37 and 38. 
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Similar to the synthesis of picolinamide 36, the final step for the preparation of N-methyl 
pyridinium catalyst 38 was the direct condensation between cinchonidine-derived amine 34 
with N-methyl picolinic acid 37, with a yield of 58% and a global reaction yield of 46%. N-
methyl pyridinium-cinchonidine 38 is a patented compound by Barrulas and Burke (WO 
2015/052656). 
Using the same synthetic procedure, the synthesis of these two very structurally similar 
compounds 36 and 38 afforded slightly different yields. One of the possible explanations for 
this fact can be related to the nature of the picolinic acid when the condensation occurs. In 
the case of the methylated picolinic acid (used for the synthesis of catalysts 38), this 
obviously presents much lower solubility in organic solvents, due to the fact that it is a 
quaternary ammonium salt. This lower solubility can certainly lead to a reduction of the 
concentration of these substrates in the reaction medium, consequently lowering the 
effective collisions of these molecules with the remaining reagents, resulting in a lower 
reaction yield.   
Another objective of this dissertation project was the development of a new N-alkylated 
class of cinchona alkaloid derivatives. The presence of a methyl group in the picolinamide 
ring, has shown to increase the catalysts activity exponentially. That led us to believe that 
the presence of other, more robust alkyl groups (such as benzyl), would also increase 
catalyst activity. And thus, we attempted to synthesize N-benzyl picolinic acid, from the 
commercially available picolinic acid and benzyl bromide with several solvents (acetonitrile, 
DMF, iPrOH, EtOH and AcOEt), at different temperatures (40-85ºC), using different heating 
techniques (such as microwave systems). Unfortunately, as expected, after many attempts 
this synthesis was not possible and we decided to not proceed with the preparation of this 
new class of catalysts.  
After synthesizing the N-methyl pyridinium 9-picolinamide-(9-deoxi)-epi-cinchonidine 
derivative, we decided to prepare a novel pyridinecarboxamide compound – an N-oxide 
picolinamide-derived cinchona alkaloid. Initially, the direct condensation method for the 
synthesis of compound 40 was attempted (Scheme 2.6), using the cinchonidine-derived 
amine 34 and the commercially available picolinic acid N-oxide 39. However, the reaction 
didn’t occur and no desired product formation was observed by 1H NMR.  
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Scheme 2.6 Attempted synthesis of the N-oxide derivative 40 by direct condensation. 
 
After the failed synthesis of catalyst 40 by direct condensation, we turned our attentions 
back to the available literature and decided to try the synthesis of this compound using a 
different method – a coupling reaction through the mixed anhydride method.249 This method 
requires more reaction steps, than the direct condensation method, and leads to the 
formation of other secondary products, however the use of milder reaction conditions and 
reduced reaction times make this a attractive alternative. Through the mixed anhydride 
method249 we were able to synthesize compound 40 (Scheme 2.7). 
 
 
Scheme 2.7 Synthesis of the N-oxide derivative 40 by the mixed anhydride method. 
 
In the first step of this reaction, the reactive intermediate 42 was formed, a mixed 
anhydride, obtained by activation of carboxylic acid 39 with isobutyl chloroformate through 
an acylic nucleophilic substitution. In the second step, the condensation of cinchonidine-
derived amine 34 with the previously formed mixed anhydride occurs, also through an acylic 
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nucleophilic substitution, with the release of carbon dioxide and isobutanol as secondary 
products. We were able to obtain the desired catalyst 39 with a yield of 55% and a global 
reaction yield of 44% (after five reaction steps).  
Following the same synthetic pathway as mentioned above and using amine 31, we were 
also able to synthesize the quinine-derived N-oxide catalyst 43 (Scheme 2.8), with a yield 
of 74% and a global reaction yield of 48% (slightly higher than observed for the cinchonidine-
derived catalysts). 
 
Scheme 2.8 Synthesis of N-oxide derivative 43 by the mixed anhydride method. 
 
Inspired by the good results obtained for N-oxide organocatalyst synthesis using the 
mixed anhydride method, we decided to apply this method in the synthesis of cinchonidine-
derived compounds 36 and 38, as well as their quinine-derived counterparts. This was done 
in order to see if there were any significant differences in terms of reaction yield, using milder 
reaction conditions and lower reaction times.   
Following the same procedure for the mixed anhydride method as described before,249 
we synthesized picolinamide-derived catalysts 36 and 44 (Scheme 2.9). The cinchonidine-
derived compound 36 was obtained with a 42% yield and a global reaction yield of 34%, 
while the quinine-derived 43 was acquired with a 40% yield and 26% global reaction yield.  
 
 
Scheme 2.9 Synthesis of compounds 36 and 44 through the mixed anhydride method. Conditions 
and reagents: a) NEt3, isobutyl chloroformate, THF. 
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 In the case of the cinchonidine-derived catalyst 36, the reaction yield obtained with this 
method was slightly lower than the one observed in the direct condensation method (74%). 
However, the global reaction yield is similar, and because the reaction time is decreased 
from 24 to 4 hours, with milder reaction conditions, we consider this method to be a better 
option to synthesize these organocatalysts.  
We also decided to synthesize the N-methyl pyridinium-derived catalysts 38 and 45 using 
the mixed anhydride method (Scheme 2.10). In this case, the cinchonidine-derived catalyst 
38 was obtained with a yield of 48% and a global reaction yield of 38%, while a yield of 45% 
and a global reaction yield of 29% was observed for the quinine-derived catalyst 45. 
 
 
Scheme 2.10 Synthesis of compounds 38 and 45 through the mixed anhydride method. Conditions 
and reagents: a) NEt3, isobutyl chloroformate, THF. 
 
The difference in yield obtained by the direct condensation method and the mixed 
anhydride method for the synthesis of catalyst 38 was only 10%. Thus, although the mixed 
anhydride method has two more reaction steps than the direct condensation, the very small 
difference in yields between them, the experimental simplicity and, once again, the fact that 
the reaction time is decreased to only four hours, henceforth makes this method the selected 
synthetic approach used for the synthesis of this class of organocatalysts. 
Because some of the catalysts were prepared by two different methods, in order to 
facilitate the comparison between them, the obtained results are summarized in table 2.1.  
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Table 2.1 Summary of the reaction and global yields obtained in the organocatalysts synthesis, with 
the respective used synthetic method. 
Entry Catalyst Method Yield (%) Yieldglobal (%) 
1 36 Direct condensation 74 59 
2 36 Mixed anhydride 42 34 
3 38 Direct condensation 58 46 
4 38 Mixed anhydride 48 38 
5 40 Mixed anhydride 52 44 
6 43 Mixed anhydride 74 48 
7 44 Mixed anhydride 40 26 
8 45 Mixed anhydride 45 29 
 
 
Having successfully synthesized the desired organocatalysts, the next step was the 
evaluation of their catalytic activity in the enantioselective reduction of the desired ketimine 
intermediates (see section 2.3).  
 
 
2.2 Synthesis of Rivastigmine Precursors 
 
Another objective of this project was the synthesis of Rivastigmine ketimine precursors, 
for subsequent catalytic hydrosilylation reaction to afford the chiral amine unit catalyzed by 
our previously prepared picolinamide based organocatalysts. As previously mentioned (see 
section 1.2.1) there are numerous methods described in the literature for the synthesis of 
Rivastigmine.191-212 Based on one of these established methodologies,250 we devised a 
general strategy for Rivastigmine synthesis, where obviously our focus was the 
hydrosilylation step.  
We choose 3’-hydroxyacetophenone 46 – a commercially available and inexpensive 
compound – as the starting material. However, when analyzing the proposed strategy for 
Rivastigmine synthesis, we observed that two different routes can be taken when starting 
from compound 46: (a) we could start with the synthesis of the carbamate intermediate 48, 
which would be later transformed into the corresponding ketimine – route A (Scheme 2.11); 
or (b) we could first synthesize the ketimine directly from compound 46 and, after the 
hydrosilylation step, synthesize the corresponding carbamate – route B (Scheme 2.15). 
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Due to these two possible strategic synthetic routes and in order to simplify the analysis 
of the obtained results, we divided the Rivastigmine precursors into two main types: 
carbamate intermediates [(3-acetylphenyl)-N-ethyl-N-methyl carbamate] and ketimines 
(derived from 3’-hydroxyacetophenone).  
 
 
2.2.1 Synthesis of (3-acetylphenyl)-N-ethyl-N-methyl carbamate 
 
As previously mentioned, the proposed synthesis of Rivastigmine can be initiated with 
the formation of carbamate 48 (Scheme 2.10), starting from commercially available 
compounds, namely 3’-hydroxyacetophenone 46 and N-ethylmethylamine 47.  
 
Scheme 2.11 Synthetic route A proposed for the synthesis of (S)-Rivastigmine. (a) Carbamate 
synthesis, (b) Ketimine synthesis, (c) Enantioselective ketimine hydrosilylation. 
 
 
Organic carbamates, and more specifically N-substituted carbamates, represent an 
important class of compounds showing various interesting properties. They have found wide 
utility in various areas, such as pharmaceuticals,251-255 agrochemicals256-258 (pesticides, 
herbicides, insecticides, fungicides, etc.), as intermediates in organic synthesis(!),259-261 for 
the protection of amino groups in peptide chemistry,262,263 and as linkers in combinatorial 
chemistry.264-266 Organic carbamates have been extensively used as intermediate for the 
synthesis of structurally diverse synthetic intermediates/molecules of biological 
significance.267-270 Therefore, considerable interest has been generated in the recent past in 
the development of efficient and safe methodologies for carbamate synthesis.  
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According to the type of carbonyl source (COCl2, CO, CO2, dimethyl carbonate, ureas, 
just to name a few), the processes for the synthesis of N-substituted carbamates mainly 
include phosgenation of amines,271,272 reductive carbonylation of nitro compounds,273,274 
oxidative carbonylation of amines,275,276 methoxycarbonylation of amines,277,278 alcoholysis 
of substituted ureas279,280 and direct synthesis from CO2, amines and alcohols.281-283 
Initially, we tried to synthesize carbamate 48 using the phosgenation process (Scheme 
2.12), the most commonly used method for the synthesis of this type of compound. This 
process is basically achieved through the reaction of an amine with an alcohol using 
phosgene or its derivatives as carbonyl source. Phosgene is, however, an extremely toxic 
compound and so we decided to use a relatively safer alternative, bis-(trichloromethyl) 
carbonate 49 (also known as triphosgene).284  
 
 
Scheme 2.12 Attempted synthesis of carbamate 48 using the phosgenation process. 
 
Carbamate synthesis using phosgene and its derivatives has been extensively studied, 
with numerous procedures described in the literature.271,272 For the synthesis of compound 
48, we attempted to use perhaps the simplest described method, that basically consists of 
combining the reagents in CH2Cl2, under anhydrous conditions, at room temperature for 8 
hours (Scheme 2.12).285 However, under these conditions, the reaction didn’t occur. The 
fact that no product formation was observed left us perplexed. A possible explanation for 
this fact may be connected to the nature of the involved compounds and so we decided to 
look more closely at the chemical properties of the starting materials. Although the starting 
secondary amine 47 is very reactive and easily couples with triphosgene, the same cannot 
be said about the starting alcohol 46. Like many other chemical structures, compound 46 
has more than one functional group, namely it has a hydroxyl group (alcohol) and a carbonyl 
group (ketone) attached to the aromatic ring in meta position relative to one another.  Whilst 
the hydroxyl group is a good nucleophile (electron donating group), the ketone is an electron 
withdrawing group that deactivates the aromatic ring by decreasing its electron density. The 
deactivation of the aromatic ring most likely also partially deactivates the hydroxyl group, 
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decreasing its reactivity and nucleophilic capacities, and prevents the desired reaction from 
occurring.  
In order to try to increase the nucleophilic strength of the hydroxyl group, we decided to 
perform the reaction using the same conditions, but this time in the presence of a base, 
namely sodium bicarbonate.286 We believed that the deprotonation of the hydroxyl group by 
this inorganic base, would increase its nucleophilic strength enough for the reaction to occur. 
However, once again, the reaction didn’t proceed proving that the synthesis of carbamate 
48 is not as “easy” as initially thought. We also tried other stronger bases, such as potassium 
hydroxide and sodium hydride, under different conditions, but no product formation was 
observed.  
Because the phosgenation process, which usually involves the use of hazardous 
compounds and generally produces highly corrosive hydrochloride as a side product, wasn’t 
very successful, we decided to attempt another, more environmentally friendly method for 
carbamate synthesis – using carbonyl di-imidazole (CDI). 
CDI is a safe and versatility acyl transfer agent that is easier to handle when compared 
with commonly used triphosgene. This reagent is commercially available in large quantities 
at low costs and it was been successfully applied in the preparation of carbonates, ureas, 
amides, urethanes, esters,287-290 or as a coupling agent for peptide synthesis291-293 in 
solution. It can be easily adopted for large scale production of several biologically active 
compounds, since it generates relatively innocuous and easy to remove by-products 
(imidazole and carbon dioxide).  
The use of CDI in carbamate synthesis is well established in the published literature.294-
303 We decided to employ similar conditions to the ones previously applied in the 
phosgenation method, but using CDI as a carbonyl source and with a longer reaction time 
(Scheme 2.13).  
 
 
Scheme 2.13 Synthesis of carbamate 48 using CDI as carbonyl source. 
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In this case, we are able to synthesize the carbamate 48, however, with a yield of only 
15%.  We expected that the nature of the starting alcohol would, once again, interfere in the 
reaction and although it was reassuring that we were able to synthesize the desired 
compound, this low yield on only the first, of the five required steps to synthesize 
Rivastigmine, was a matter of concern. At this point, in an attempt to optimize reaction 
conditions and subsequently increase its yield, we decided to try other methods from the 
wide range available in the literature. Starting with the use of bases to deprotonate the 
alcohol, such as sodium bicarbonate,286 potassium hydroxide,304 triethylamine and sodium 
hydride286, using different solvents (dichloromethane, toluene, THF), with temperatures 
ranging from 25 to 150ºC, we were incapable of replicating the synthesis of carbamate 48. 
We also tried some alternative methods using UV light and microwave irradiation, but were 
once again unsuccessful.  
As a last effort, we applied a reported method using an ytterbium catalyst305 for the 
synthesis of carbonate intermediate 51 (Scheme 2.14). While the synthesis of this 
intermediate was possible, with a yield of 48%, unfortunately, the next step – the 
incorporation of the starting alcohol – was unsuccessful!  
 
 
Scheme 2.14 Synthesis of intermediate 51 and attempted synthesis of carbamate 48. 
 
The attempt to use the ytterbium catalyst for the synthesis of the intermediate starting 
with CDI and the alcohol 46 (instead of the amine 47) was also carried out. However, in this 
case, no product formation was observed. 
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Disappointed by the results that were obtained in the synthesis of carbamate 48, we 
decided to abandon this synthetic pathway for Rivastigmine and focus on the other proposed 
route B.  
 
 
2.2.2 Synthesis of ketimines derived from 3’-hydroxyacetophenone 
 
Nitrogen and oxygen atoms possesses very similar reactivity (since they have similar 
electronegativity values), yet a ketone and an amine group obviously have very different 
chemical characteristics. As previously mentioned, a ketone is an electron withdrawing 
group that deactivates the aromatic ring, which may be a contributing factor for the difficulties 
observed in carbamate 48 synthesis. However, an amine is an electron donating group that 
activate the aromatic ring, adding electron density to the π system making it more 
nucleophilic. This led us to postulate that the carbamate synthesis would be easier to 
accomplish with an amine group in the meta position relatively to the hydroxyl. And so we 
turned our attention to the proposed synthetic route B (Scheme 2.15), where the 
corresponding amine of 3’-hydroxyacetophenone is prepared first, to be posteriorly applied 
in the carbamate synthesis.  
 
 
Scheme 2.15 Synthetic route B proposed for the synthesis of (S)-Rivastigmine. (a) Ketimine 
synthesis, (b) Enantioselective ketimine hydrosilylation, (c) Carbamate synthesis. 
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The asymmetric reduction of the C=N bond is one of the most straightforward approaches 
to afford chiral amines. Before we could study this asymmetric reduction reaction, we first 
had to explore the synthesis of a range of imines derived from commercially available 3’-
hydroxyacetophenone, i.e. conduct a number of model reactions.  
Imines are important intermediates in the synthesis of various biologically active N-
heterocyclic compounds and in industrial synthetic processes.306-309 Imines which have a 
structure analogous to ketones are referred to as ketimines. Ketimines are represented by 
the general formula R,R1-C=N-R2, where R, R1 and R2 could be an alkyl or an aryl group 
(Scheme 2.16). These compounds can also be called Schiff bases,321 when R2 is not a 
hydrogen atom, and its stability is granted by the substituent on the nitrogen.  
Information on the synthesis and chemistry of imines can be found scattered throughout 
the literature.310-321 Significant progress has been made in recent years in the development 
of methods for imine synthesis, which include condensation of aldehydes/ketones with 
amines, addition of aryl halides and liquid ammonia to aldehydes/ketones, hydroamination 
of alkynes, oxidative coupling of amines to give imines, oxidative coupling of alcohols and 
amines, dehydrogenation of secondary amines, coupling of aldehydes/ketones with nitro 
compounds and the reaction between chemical equivalents of aldehydes/ketones and 
amines.322  
The synthesis of ketimines if often accomplished by the direct condensation of ketones 
with primary amines according to the mechanism presented in Scheme 2.15. The 
equilibrium of this reaction usually favors the carbonyl molecule and the amine, but it can be 
forced towards the product by azeotropic distillation of the formed water, using a Dean-Stark 
trap, or using drying agents or even molecular sieves.  
 
 
Scheme 2.16 Proposed mechanism for the synthesis of ketimines from ketones and amines.323 
 
There are numerous primary amines, with a wide range of structurers, available for 
ketimine synthesis. However, from a logical synthetic point of view, only primary amines with 
relatively easy removable activating groups were chosen. This directly eliminates the use of 
some well-known amines, such as for example tosyl, nosyl, mesyl and BOC derivatives, 
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which are usually very difficult groups to remove, requiring harsher conditions, and are also 
more difficult to synthesize with ketones.  
To the best of our knowledge, the ketimine 53 obtained from 3’-hydroxyacetophenone 
and benzylamine has not yet been reported. Due to this fact and that benzyl is a relatively 
easy removable group, we decided to focus our attention on the development of these N-
benzyl ketimines.  
We first attempted the synthesis of ketimine 53 by using a very well-known literature 
procedure324 (Scheme 2.17) that uses BF3.Et2O as a catalyst to initiate the condensation 
reaction. However, after purification by liquid column chromatography, only the starting 
materials were detected with no product formation observed. 
  
 
Scheme 2.17 Attempted synthesis of N-benzyl ketimine 53 using BF3.Et2O as a catalyst. 
 
We then tried another well-known procedure from the literature.325 In this case, titanium 
ethoxide was used as catalyst in THF (under reflux) and in the presence of 4 Å molecular 
sieves (MS), and, once again, after the purification step, no product formation was detected, 
having only retrieved the starting materials. Pyridinium p-toluenesulfonate was also tested 
as the catalyst for this reaction, in CH2Cl2 (under reflux) and in the presence of 4 Å MS,326 
however the reaction didn’t proceed.  
At this point, we started to suspect that two things could be occurring: (1) ketimine 53 
synthesis is not, for some reason, possible; or (2) the ketimine 53 when formed is very 
unstable and hydrolyzes back to the starting ketone and amine. It is well-known that imines, 
in the presence of an aqueous medium, easily suffer hydrolysis. That’s the reason why all 
the direct condensation methods require a drying agent or a Dean-Stark apparatus.  
To try to clarify which, if any, of these two possibilities was occurring, we attempted to 
perform a 1H NMR analysis of the obtained crude mixtures. However, no definitive 
conclusions were possible due to the disarray of signals observed in the spectrum. 
Nevertheless, we decided to try a few more know procedures for the synthesis of ketimine 
53. Ley327 developed a simple method for the synthesis of complex ketimines, using sodium 
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bicarbonate, in toluene and 4 Å MS, under anhydrous conditions at 100ºC. When applied to 
our desired ketimine this method was unsuccessful and no product formation was observed.  
The use of microwave (MW) irradiation in imine synthesis has been studied extensively 
over the last few decades, and it has already being established as an effective alternative 
to traditional methods. Typically, the described MW procedures use clay as catalyst and 
drying agents for this organic reaction. We attempted to synthesize ketimine 53 under MW 
irradiation using montmorillonite K10, in acetonitrile and toluene213,328, and, once again, only 
the starting materials were recuperated.  
Frustrated with these poor results, we came to the conclusion, that no matter the reason, 
we needed to devise a new strategy to synthesize the desired ketimines. We decided to turn 
to the “oldest trick” in the organic chemist’s book – the use of protecting groups. We 
postulated that the protection of the phenolic group would stabilize the ketimine structure, 
allowing its synthesis and isolation. Because in order to synthesize Rivastigmine we would 
need to remove the benzyl group attached to the amine, we decided to protect the hydroxyl 
with another benzyl group, forming a benzyl ether (Scheme 2.18). This would allow us to 
remove the two protecting groups in one single step.  
 
 
Scheme 2.18 Synthesis 3’-benzyloxy-acetophenone 54. 
 
O-benzyl protected compound 54 was synthesized using a very well-known literature 
procedure,329 with an isolated product yield of 57%.  
Having protected the hydroxyl group, we attempted to synthesize the corresponding N-
benzyl ketimine 55 using the first previously described procedure. However, to our disbelief, 
with BF3.Et2O as catalyst, the reaction didn’t occur again. We decided to adapt all the 
previous described methods for the synthesis of ketimine 53, in the synthesis of compound 
55. Unfortunately, none of these methods afforded the desired compound.  
Despite these discouraging results, we tried two new methods described in the literature. 
Miyaura330 reported imine synthesis using CuSO4.5H2O, MgSO4 in CH2Cl2 and Ruano and 
Cid331 developed a highly efficient method for the synthesis of aldimines in the presence of 
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pyrrolidine as catalyst. Only starting material was recovered and no product formation was 
observed in both cases.  
In order to try to understand what was happening, we decided to again perform a 1H NMR 
analysis of the crude mixtures, in this case, of the one obtained using the method developed 
by Ley.327 After careful analysis of the NMR spectrum, we came to the conclusion that 
ketimine 55 was present in a very small amount. However, after purification by liquid column 
chromatography on silica gel, only the starting materials were detected. This led us to 
believe that this ketimine is very unstable under acidic conditions, hydrolyzing to the ketone 
and amine very easily. The detection of ketimine in the crude mixture gave us hope that 
product synthesis was possible, but other purification methods needed to be used. We 
unsuccessfully tried liquid column chromatography with several different conditions. We also 
tried to purify the desired ketimine by micro distillation, but this was not feasible, due to the 
very high boiling and melting point of the starting materials and the unknown chemical 
properties of the product.  
At this point, we started to believe that the protection of the phenolic group was enough 
to stabilize the ketimine structure for its synthesis, but not for its isolation. We decided to 
focus on ketimine synthesis, leaving its isolation on “standby”.   
In a desperate attempt to find a method to synthesize the desired ketimine, we learned 
that a significant difference in the chemical shift between the starting ketone and ketimine 
was observed.213 In compounds with very similar structure to the ketimine 55, the chemical 
shift of the methyl group (a singlet) changes from 2.6 (in the ketone) to 2.25-2.35 ppm (in 
the ketimine). This clear difference can be used to observe the presence of the desired 
ketimine and subsequently determine the reaction yield by NMR. Henceforth, all the yields 
for the ketimines synthesis were determined by 1H RMN, using the signal characteristic of 
the methyl group. 
Inspired by this fact, we used a very simple direct condensation method described in the 
literature.213 We were finally able to synthesize the O-benzyl protected ketimine 55, with a 
yield of 50% by just allowing the starting materials to react in toluene at room temperature 
for 18h in the presence of 4 Å MS and under anhydrous conditions (Scheme 2.19). To be 
sure that isolation was not possible, purification by liquid column chromatography and micro 
distillation were unsuccessfully attempted.  
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Scheme 2.19 Synthesis of N-benzyl ketimine 55 from the corresponding O-benzyl protected 
ketone. 
 
At this point, under the assumption that product purification was not achievable, we 
decided that no compound obtained with a yield lower than 90% would be used in the study 
of the organocatalysts in the hydrosilylation of ketimines – the subsequent step of 
Rivastigmine synthesis. Thus, we needed to increase the yield obtained in the synthesis of 
ketimine 55. There were a number of parameters that can be screened in this reaction, such 
as solvent, temperature and reaction time. We started with a temperature screening and, 
fortunately, found that a yield of 91% could be achieved at 60ºC.  
Enthusiastic about these results, we decided to synthesize other ketimines with similar 
structures. A very short list of primary amines with relatively easy removable groups are 
available for imine synthesis, being most of which benzyl derived structures. We decided to 
use phenyl derived amines, namely aniline, for the ketimine synthesis. Although phenyl 
groups are harder to remove than benzyl groups, their de-protection can be considered 
relatively easy when compared with tosyl and nosyl groups.329  
Using the same conditions as previously described, we synthesized N-phenyl ketimine 
57, obtained from the O-benzyl protected ketone 54 and commercially available aniline 56, 
with a yield of 90% (Scheme 2.20).  
 
 
Scheme 2.20 Synthesis of N-phenyl ketimine 57 from the corresponding O-benzyl protected 
ketone. 
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In the case of compound 57, the removal of the protecting groups cannot be done in one 
single step, since they are orthogonal and require different de-protection conditions, thus 
adding an extra step to Rivastigmine synthesis. This opened the precedent for the use of 
other groups for hydroxyl protection. Thus, in order to have a wider range of ketimines, we 
decided to use a methyl group to protect the phenolic group. O-Methyl protected ketone 58 
was synthesized by the same method used for the benzyl protection (Scheme 2.21),329 with 
an isolated product yield of 61%. 
 
 
Scheme 2.21 Synthesis of 3’-methyloxy-acetophenone 58. 
 
Having successfully prepared O-methyl protected ketone 58, the aniline and benzylamine 
derived ketimines were synthesized with the same previously established conditions 
(Scheme 2.22). The N-benzyl ketimine 59 was obtained with a yield of 92% and a yield of 
94% was obtained in the preparation of the N-phenyl ketimine 60.  
 
 
Scheme 2.22 Synthesis of N-benzyl ketimine 59 and N-phenyl ketimine 60. 
  
Despite the fact that the yields obtained for the ketimine synthesis were very close to the 
self-imposed limit of 90%, the increase of reaction temperature to just 80ºC was found to 
decrease the reaction yield by more than 10%, and thus 60ºC was established as the optimal 
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reaction temperature. We synthesized four O-protected ketimines with yields between 90 
and 94%, and its enantioselective reduction using the previously prepared organocatalysts 
is discussed is section 2.3.  
 
 
2.2.3 Synthesis of ketimines derived from 3’-bromoacetophenone  
 
Inspired by a carbamate synthesis method reported in the literature,305 we conceived a 
third synthetic pathway to Rivastigmine – route C (Scheme 2.23). This pathway differs from 
the two previously presented routes not just in its starting material (3’-bromoacetophenone) 
but also in the carbamate synthesis method, which in this case is a metal catalyzed (usually 
palladium) C-O coupling.356-362  
 
 
Scheme 2.23 Synthetic route C proposed for the synthesis of (S)-rivastigmine. 
 
 
In order to obtain the target compound by this synthetic pathway, the separate synthesis 
of the chiral amine (derived from 3’-bromoacetophenone) and the carbamate intermediate 
62 needed to occur first. Due to the interest of this study, we only focused our initial attention 
on the synthesis of the chiral amines derived from 3’-bromoacetophenone and consequently 
its corresponding ketimines.  
Analogous to the previous synthetized ketimines, we decided to prepare N-benzyl and 
N-phenyl ketimines from the corresponding 3’-bromoacetophenone 61. An initial attempt to 
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synthesize these ketimines using the previously described method,324 in which BF3.Et2O acts 
as a catalyst, was made. However, no product was observed for both ketimines. Thus, we 
decided to synthesize these compounds with the same procedure previously used for the 
preparation of the O-protected ketimines (Scheme 2.24).213 The same rule of a required yield 
superior to 90% was imposed.  
 
 
Scheme 2.24 Synthesis of N-benzyl protected ketimine 63 and N-phenyl protected ketimine 64. 
 
The N-benzyl ketimine 63 was synthesized with an astonishing yield of 95% and an 
equally impressive yield of 94% was obtained in the preparation of the N-phenyl ketimine 
63. The enantioselective reduction of these two synthesized 3’-bromoacetophenone derived 
ketimines was studied.  
 
 
2.3 Asymmetric Hydrosilylation of Ketimines 
 
At this point, having successfully synthesized the 9-picolinamide-cinchona alkaloid 
derivative catalysts (see section 2.1) and the ketimines intermediates of Rivastigmine (see 
section 2.2), we could now proceed with the main objective of this dissertation project – 
study the role of the prepared organocatalysts in the enantioselective reduction of these 
ketimines.  
With the hydrosilylation of the ketimine intermediates in mind, and based on existing 
literature,180,213,222,224,225,228 we decided to perform a screening of the different 
organocatalysts using 3.5 equivalents of trichlorosilane in the presence of 10 mol% of the 
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catalyst, in anhydrous dicloromethane at room temperature for 18 hours. The results are 
divided into the N-phenyl and N-benzyl ketimine reduction and can be seen in table 2.2 and 
2.3, respectively.  
Chiral amines 66,363,364 67,365-369 69370 and 70371-373 have been previously reported in the 
literature and, thus, the stereochemistry of these four compounds was identified by 
comparison with the available published results. Amines 65 e 68 have never been described 
in the literature, but, through comparison with similar chemical structures (such as the 
mentioned above four chiral amines), we identified the stereochemistry of these amines.  
 
Table 2.2 Asymmetric reduction of N-phenyl ketimines with picolinamide-derived cinchona 
alkaloid organocatalysts. 
 
Entry R Catalyst Yield (%)a e.e (%)b 
1 OBn 36 97 79 
2 OBn 38 99 85 
3 OBn 40 77 <10 
4 OBn 43 86 <10 
5 OBn 44 91 71 
6 OBn 45 99 77 
7 OMe 36 98 77 
8 OMe 38 94 80 
9 OMe 40 71 <10 
10 OMe 43 67 <10 
11 OMe 44 99 68 
12 OMe 45 99 70 
13 Br 36 97 81 
14 Br 38 96 78 
15 Br 40 75 <10 
16 Br 43 83 <10 
17 Br 44 99 79 
18 Br 45 99 68 
 a Yields of isolated products. 
b Determined by HPLC on a chiral stationary phase. 
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Analysis of the results obtained in the reduction of the N-phenyl ketimines (table 2.2) 
allowed us to make some simple but important initial observations. First, it is important to 
underline that all the organocatalysts were effective in the reduction of ketimines with HSiCl3, 
however only four of them (compounds 36, 38, 44 and 45) exhibited enantioselective 
properties in the synthesis of chiral amines. The desired enantiomer (S) was obtained with 
these four catalysts, with excellent yields (91-99%) and moderate to good enantiomeric 
excess (68-85%). Although these four structures are derived from both cinchona alkaloids 
used in this project, no significant discrepancies, in terms of yield and enantioselectivity, 
were observed between them. Thus, with differences of only up to 10% in enantiomeric 
excess and yield, we can claim that catalysts derived from quinine and cinchonidine have 
very similar catalytic properties when applied on the enantioselective reduction of these 
ketimines.  
Based on models previously reported in the literature, Barrulas et al.180 proposed a 
hypothetical transition state for the hydrosilylation of ketimines with organocatalysts 36 
(Figure 2.1). They postulated that, in the case of the non-methylated catalysts, at first, it is 
expected that HSiCl3 activation occurs through the coordination of the silane and two of the 
three Lewis bases existing in the picolinamide, which will result in the release of a hydride. 
Simultaneously, a prochiral ketimine molecule can interact with this intermediate, either 
through π-π interactions between its phenyl groups and the aromatic systems of the 
picolinamide, or by hydrogen bonds between the nitrogen of the ketimine and the acidic 
hydrogen of the picolinamide. Thus, it is more likely that an accentuated exposure of the Si-
face of the ketimine to the “inside” of this intermediate occurs, allowing an enantioselective 
attack of the release hydride, which would explain the preferred (S) enantiomer obtained 
with this type of catalyst.178 
 
Results and Discussion 
 
 
69 
 
 
Figure 2.1 Barrulas178 proposed transition state involving picolinamide 36, a prochiral ketimine and 
HSiCl3. 
 
In the case of the N-oxide catalysts 40 and 43, amines were obtained in their racemic 
form – which was somewhat expected. There have been some recent reports of HSiCl3 
deactivation by N-oxide structures,221,222,224,228 but, at the time, we believed that the diverse 
and robust structure of the catalysts would still allow enantioselectivity, even with reduced 
enantioselective properties. It was originally conceived that the N-oxide oxygen would 
coordinate with HSiCl3, however, due to the extra bond (N-O), it is likely that the transition 
state becomes less compact, or less rigid with greater conformational flexibility leading to 
the enantioselectivity loss.   
Although the results obtained for catalysts 36, 38, 44 and 45, in terms of 
enantioselectivity, are very similar, we can observe a slight improvement in the N-methylated 
class of these compounds. Indeed, generally speaking, compound 38, the N-methylated 
cinchonidine-derived catalyst, gave the best results, with the overall highest obtained 
enantiomeric excess of 85% and an excellent yield of 99%.   
To try to understand the reason why these catalysts, that possess an N-methylated 
picolinamide in their structure, afford better enantiomeric excess and, in some cases, better 
yields, we need to look back at the proposed transition state.178 This minor difference 
observed in the enantioselectivity might be due to a slight steric hindrance generated by the 
methyl group, which may, somehow, “reinforce” the proper orientation of either the substrate 
or the activated silane during the proposed enantioselective transition state (Figure 2.2). 
Due to the charge on the pyridine ring, which should be delocalized around the ring, the π-
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π interaction (which will be more a π-cation interaction) may be stronger than of the previous 
π-π interaction obtained in the case of the non-methylated catalysts. However, further 
theoretical studies (such as DFT calculations) are required to better understand the reaction 
mechanism associated with these types of structures.  
 
 
Figure 2.2 Barrulas178 proposed transition state involving compound 38, a prochiral ketimine and 
HSiCl3. 
  
Interestingly the meta substituent of the aromatic ring of the ketimines, didn’t seem to 
have much effect on the obtained results. Indeed, the hydrosilylation of O-protected 
ketimines gave very similar results to the reduction of the bromine meta-substituted 
ketimines. 
Thrilled with these results, we performed the reduction of the N-benzyl ketimines with our 
six prepared organocatalysts (Table 2.3). 
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Table 2.3 Asymmetric reduction of N-benzyl ketimines with picolinamide-derived cinchona 
alkaloid organocatalysts. 
 
Entry R Catalyst Yield (%)a e.e (%)b 
1 OBn 36 57 29 
2 OBn 38 49 33 
3 OBn 40 14 <10 
4 OBn 43 51 <10 
5 OBn 44 71 28 
6 OBn 45 67 45 
7 OMe 36 52 31 
8 OMe 38 45 41 
9 OMe 40 63 <10 
10 OMe 43 30 <10 
11 OMe 44 60 32 
12 OMe 45 69 42 
13 Br 36 56 14 
14 Br 38 59 30 
15 Br 40 76 13 
16 Br 43 15 <10 
17 Br 44 52 30 
18 Br 45 66 38 
 
 
 
Unlike what was previously observed for the N-phenyl ketimines, slightly disappointing 
results were obtained for the reduction of the N-benzyl ketimines. Although, once again, all 
the organocatalysts were effective in the reduction of ketimines with HSiCl3, lower yields 
(14-79%) and enantiomeric excess (13-45%) were observed. The same organocatalysts 
afforded results with differences ranging from 30-60% between the reduction of the N-phenyl 
and N-benzyl ketimines.  
a Yields of isolated products. 
b Determined by HPLC on a chiral stationary phase. 
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Once again, no significant differences on catalyst activity were observed between the 
three different ketimines structures. Likewise, only very small changes were observed 
between the quinine and cinchonidine derived catalysts, corroborating our previous 
statement, that quinine and cinchonidine derived catalysts possess very similar catalytic 
properties on the hydrosilylation of ketimines.  
The N-oxide catalysts 40 and 43, once more, gave the amine products in their racemic 
form and the N-methylated catalysts 38 and 45 afforded some of the best yields (45-69%) 
and the best enantioselectivity (45%). These results led us to conclude that N-oxide 
picolinamide-derived cinchona alkaloids are not efficient catalysts for the enantioselective 
reduction of ketimines. They also allow us to claim that the N-methylated class are the best 
and most promising catalysts in the enantioselective hydrosilylation of ketimines.  
Unfortunately, (despite our best efforts) we do not know for sure the reason why there’s 
such a significant difference between the hydrosilylation of the N-phenyl and N-benzyl 
ketimines with the same organocatalysts. The instability of the ketimine structure may be a 
possible explanation. Another possibility is that the N-phenyl ketimines must give a more 
compact transition state structure, inductive of better enantiofacial selectivity.  However, due 
to the fact that the transition state of the enantioselective reduction of ketimines with this 
class of organocatalysts has not yet been completely established, there are consequently 
many questions regarding the influence of the ketimine structure on the reaction efficacy.  
 
It is worth nothing that these six synthesized organocatalysts are just some 
representatives of a wide class of multifunctional chiral Lewis bases, as chiral catalysts for 
stereoselective reductions, characterized by multiple modes of action.213 Indeed, 
compounds 36 and 44 feature the picolinamide group as coordinating unit to HSiCl3, and 
the basic quinuclidine ring that can also play a role in the activation of the reducing agent, 
while catalysts 38 and 45 might still behave as a bifunctional catalyst, presenting a different 
coordination mode, with the carboxyamide group and the quinuclidine nitrogen group. The 
cinchona scaffold is very versatile but, at some levels, is still a mystery. Further studies are 
required to establish the exact mode of action of each of these catalysts, in order to better 
understand the mechanisms of the reactions in which they are involved, such as in the 
enantioselective reduction of ketimines. 
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2.4 Immobilization of Organocatalysts  
 
Even though the enantioselective reduction of ketimine intermediates of Rivastigmine 
wasn’t as successful as we wished, the great versatility and excellent levels of 
enantioselectivity previously showed by 9-picolinamide-Cinchona alkaloids in this 
organocatalyzed reaction,180,213 make the immobilization of this class of catalysts extremely 
attractive from a possible industrial application point of view. 
Homogeneous asymmetric catalysis possesses some disadvantages that limit their 
application in industrial processes, such as the high cost of the chiral catalysts and its low 
versatility, since many of the very selective catalysts have only been developed for reactions 
with selected model substrates. In addition, for many of the developed catalysts little 
information is available on catalysts selectivity, activity and productivity. Also, due to 
difficulties in catalyst handling, separation and recycling, the majority of homogenous 
catalysts are not available for commercial applications on an industrial scale.332  
Heterogenization of homogenous organocatalysts represents a logical approach to 
overcome these problems. The heterogenized catalysts can potentially provide easily 
recyclable and reusable solid catalysts that have uniform and precisely engineered active 
sites similar to those of their homogeneous counterparts, and therefore combine the 
advantages of both homogeneous (high stability, high enantioselectivity and good 
reproducibility) and heterogeneous (easy separation, stability and reuse) systems.333 
Considering this, there’s a growing interests in the immobilization of organocatalysts to solid 
supports.334-340 Over the past few decades, many immobilization approaches have been 
explored, including the attachment of the chiral catalyst to organic polymers, dendrimers, 
membrane supports and porous inorganic oxides and via biphasic systems.341 
To date, as far as we know, the immobilization of picolinamide-derived cinchona alkaloids 
has not been reported in the literature. And so, motivated by the advantages of 
heterogeneous catalysis, we decided to perform some studies on the immobilization of 9-
picolinamide-Cinchona alkaloid derivatives (Figure 2.3). 
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Figure 2.3 General schematic representation of heterogenized 9-picolinamide-Cinchona alkaloid 
derivatives. 
 
The choice of the solid support is very important, since it is decisive in determining the 
experimental set-up for performing the reaction and also dictates the recovery and the 
recycle techniques. Additionally the morphology of the material plays a key role in the 
selection of a suitable field of application of the immobilized catalytic species. There is 
another crucial point that needs to be mentioned: the synthesis of the supported catalyst 
should exploit a starting material comparable in cost and synthetic complexity to that of the 
compound used for the synthesis of non-supported catalysts. Several different types of 
supports have been used for the immobilization of chiral catalysts, the most popular being 
inorganic materials (like silica, zeolites or alumina), soluble organic polymers (PEG, 
polymethylhydrosiloxan, polyacrylic acid, polyamidoamines, just to name a few) and 
insoluble polymeric resins.333  
Based on the work developed by Benaglia et al.342 on the immobilization of 9-amino-
cinchona alkaloid derivatives, we decided to proceed with the immobilization of our 9-
picolinamide-cinchona alkaloid derivatives on two different types of solid supports – a silica 
and a polymer. Although preliminary studies performed by the Benaglia group333,342-345 in 
trichlorosilane-mediated reductions, using catalysts with different structures, showed that 
silica-supported catalysts are usually less efficient than the polystyrene-supported systems, 
we decided to study both materials because it is of interest to compare these two in the 
immobilization of the picolinamide-derived catalysts.  
Due to organocatalysts availability issues, we only studied the immobilization of some 
selected picolinamide-derived catalysts, namely catalysts 36, 44 and 45 (for silica) and 
catalyst 44 (for the polymer).  
 For the synthesis of the silica-supported catalysts we opted for a postgrafting 
functionalization of an already synthesized material with a chiral trialkoxysilane tether 
according to previously established procedures from the literature.343 Commercially 
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available mesoporous silica nanoparticles were used as a solid support (i.e. the silica matrix) 
for all three catalysts.  
The immobilization of the three catalysts in the commercial silica started with a platinum 
catalyzed hydrosilylation with trimethoxysilane (Scheme 2.25). The insertion of a silane 
group, in the vinyl group attached to the quinuclidine ring, previous to the grafting, is a 
required step for a more efficient immobilization on the silica. The formation of the 
enantiopure trialkoxysilane 71 was confirmed by 1H NMR with the disappearance of the 
multiplets at 4.95-4.05 and 5.74-5.80 ppm (of the double bond of the vinyl group) and the 
appearance of a singlet at 3.55 ppm (of the methoxyl groups). Likewise, using the same 
methodology, two analogues of 36 were tethered to a trimethoxysilane group, to give the 
products 71a and 71b, respectively.    
 
 
Scheme 2.25 Hydrosilylation reaction for the insertion of a silane group in the desired compound. 
  
 
Having successfully performed the hydrosilylation reaction, we grafted the 
trialkoxysilanes 71, 71a and 71b to mesoporous silica in toluene at 80ºC for 48h to afford 
the desired silica-supported catalysts (Scheme 2.26). The catalysts were isolated by 
filtration, washed with a mixture of organic solvents and dried under high vacuum to remove 
any trace of remaining solvent.  
 
Results and Discussion 
 
 
76 
 
 
Scheme 2.26 Synthesis of the silica-supported 9-picolinamide-cinchona alkaloid derivatives. 
 
It is worth mentioning that the presented loading of the supported catalysts is an 
estimated value roughly determined by the amount of trialkoxysilane recuperated from the 
organic washing solvents. Further analysis (such as elemental analysis, solid-state NMR, 
SEM, TGA, just to name a few) of the synthesized materials is required to precisely 
determine not just the loading of these supported catalysts but also its morphologic 
characteristics.  
The synthesis of the polymer-supported catalysts turn out to be more complex and 
difficult than their silica-supported counterpart. The general strategy to prepare polystyrene 
supported 9-picolinamide-cinchona derivatives involves the introduction of a linker on the 
quinuclidine ring suitable for radical polymerization. However, upon analyzing the synthetic 
pathway for polymer-supported 9-amino-cinhona alkaloid derivatives developed by Benaglia 
et al.,342 we observed that three slightly different routes could be taken to synthesize the 
polymer-supported catalysts. The catalyst loading (mmol/g) for the polymer-supported 
catalysts were determined by the stoichiometry of the reagents in the polymerization 
mixture.  
In route 1 the picolinamide group is inserted in the catalyst after the polymerization step 
(Scheme 2.27). The synthesis starts with the conversion of the double bond of commercially 
available quinine into a triple bond to afford compound 75 with a yield of 62%. Compound 
75 was subjected to a CuAAC click reaction with a previously synthetized azide, in order to 
establish a styrene moiety ready for polymerization. Alcohol 76 was then converted into 
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amine 77, by the same methodology as previously described for the non-supported 
catalysts178 (see section 2.1), isolated in 58% overall yield after only one chromatographic 
purification. Afterwards this amine was employed in a radical co-polymerization under 
Fréchet-type conditions, with divinylbenzene in the presence of azobis(isobutyronitile) 
(AIBN) as radical initiator and toluene and 1-dodecanol as porogenic solvents. Lastly, using 
the direct condensation method previously described,242 a picolinamide group was added to 
compound 78, affording the polymer-supported catalyst 79 with a loading of 0.57 mmol/g. In 
this case, the polymerization of 9-amino-quinine was performed by Riccardo Porta and we 
only performed the last modification step (the adition of the picolinamide group). 
 
Scheme 2.27 Synthesis of polymer-supported catalyst 79 via route 1. 
 
The uncertainty associated with the actual structure of the catalyst is a considerable 
disadvantage of this proposed synthetic pathway. There is a substantial risk that not all the 
amine catalyst 78 was transformed into picolinamide catalyst 79, which will obviously affect 
and undermine the desired reaction efficacy. Performing a simple catalytic test reaction, 
such as the reduction of ketimines, can be an alternative to the more expensive and arduous 
analysis techniques. For that reason, we performed the hydrosilylation of a very simple 
ketimine with catalyst 78 and the supposedly prepared catalyst 79. Compound 78 afforded 
the corresponding amine of the N-PMP imine of acetophenone as a racemic mixture, while 
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with 79 an enantiomeric excess of 23% was obtained. Although there is a significant 
difference between the two tested compounds, the enantioselectivity demonstrated by 
catalyst 79 is much lower than its non-supported counterpart (80% e.e.).180  
Two assumptions can be taken from these results: 1) the supported catalyst is much less 
efficient than the non-supported catalysts, possibly due to chemical effects of the surface 
material; or 2) it not just catalyst 79 but also a large quantity of remaining untransformed 
catalyst 78, which are competing with one another. The later possibility is the more plausible 
explanation. By altering the structure of an already polymerized catalysts, we need further 
structural analysis (mainly solid-state NMR) to know the exact changes that happened. 
Without a thorough analysis and characterization of the immobilized catalyst, no correct 
conclusions can be made about the synthesized catalyst, which makes this route inadequate 
for the synthesis of these polymer-supported picolinamide catalyst.  
Proposed synthetic route 2 solves the problems of route 1, since the desired monomer 
(with the picolinamide structure in the catalyst) is prepared before the polymerization step 
(Scheme 2.28). In this synthetic route we performed the synthesis of amine 77 as previously 
described for route 1. We then attempted to transform this amine into its corresponding 
picolinamide, using the mixed anhydride method previously described.249 However, due to 
lack of experience of working with this unstable intermediates, the isolation of picolinamide 
80 was unsuccessful.  
 
Scheme 2.28 Attempted synthesis of polymer-supported catalyst 79 via route 2.  
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1H NMR analysis of the crude mixture 80 allowed the observation of the desired product, 
however, after purification by liquid column chromatography on silica gel, no product was 
detected. For some reason (unknown to us), the product possibly degraded during the 
purification step. Despite this setback, we believe that this synthetic pathway can be very 
efficient for the preparation of polymer-supported 9-picolinamide-cinchona alkaloid 
derivatives.  
The last proposed synthetic route is very similar to route 2. The main difference between 
these two synthetic pathways resides in the step where the styrene moiety is inserted. In 
route 3 (Scheme 2.29), after the commercially available quinine is converted into triple bond 
containing compound 75, the alcohol was first converted into amine 81 with an overall yield 
of 80% (instead of the click reaction to insert the styrene moiety). The amine was then 
transformed into its corresponding picolinamide 82 in a yield of 73%. The picolinamide was 
then ready to be subjected to the click reaction, in order to establish a styrene moiety ready 
for polymerization. However, some problems arose during this step. The reaction didn’t 
proceed when using catalytic amounts (0.05 equiv.) of copper iodide. Copper, the catalyst 
used in the click reaction, has strong affinity for amines and, in their presence, the amine 
coordination to the metal is preferable. In this case, we believe that by complexing with the 
9-picolinamide group, copper was removed from the reaction medium, remaining in a 
“pocket” near the amine. 
  
 
Scheme 2.29 Attempted synthesis of polymer-supported catalyst 79 via route 3.  
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The click reaction can also occur by thermal induction, but, in this case, there is no 
stereochemical control, which is undesired. Interestingly we postulated that by using 
stoichiometric amounts of copper the reaction could be forced to work, because, although a 
large percentage of the used copper would be complexed with the amine, there would still 
be a catalytic amount left for the desired reaction. Indeed, when using 1.2 equivalents of 
copper iodide the formation of crude product 80 was observed by 1H NMR. However, like 
the situation observed in route 2, product isolation was not possible. Although the detection 
of compound 80, even in small amounts, gives us hope for the synthesis of polymer-
supported catalyst 79, we believe that synthetic route 3 is not the most adequate pathway, 
since stoichiometric amounts of copper need to be used.  
Unfortunately, the efficient synthesis of polymer-supported 9-picolinamide-cinchona 
alkaloid derivatives was not possible during the time frame of this dissertation project. Yet 
we believe that proposed synthetic route 2 is the most efficient pathway to prepare these 
supported catalysts.  
The applications of supported 9-picolinamide-cinchona alkaloid derived catalysts in 
continuous flow systems was one of the objectives that we had in mind when we first started 
to work on the immobilization of these catalysts. The use of chiral supported organocatalysts 
under continuous flow conditions offers a great opportunity to combine a powerful 
methodology, like organocatalysis, with other enabling technologies,346 opening new 
avenues towards the automated synthesis of complex molecules.347-351 
Although we weren’t able to adequately prepare the polymer-supported catalyst, three 
silica-supported catalysts were synthesized. Before we could apply the immobilized 
catalysts in continuous flow systems, a preliminary assessment of catalysts activity needed 
to be performed under batch conditions. For this effect, the reduction of N-PMP imine of 
acetophenone with HSiCl3 and the prepared silica-supported catalysts 72, 73 and 74 was 
studied and the obtained results are presented in table 2.4.  
The N-PMP imine of acetophenone was already available to be used in the hydrosilylation 
reaction, having been previously prepared by another member of the Benaglia group, using 
well-known literature procedures.213  
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Table 2.4 Asymmetric reduction of N-PMP imine of acetophenone with silica-supported 9-
picolinamide-cinchona alkaloid derivatives. 
 
Entry Catalyst Yield (%)a e.e (%)b 
1 72 64 30 
2 73 >99 62 
3 74 55 27 
 
 
 
The enantioselective reduction catalyzed by the three silica-supported catalysts afforded 
lower results than expected. Good to excellent yields (55-99%) were observed, while only 
low to modest enantioselectivities (27-62%) were obtained. Catalysts 73 afforded the best 
results in terms of both yield (>99%) and enantioselectivity (62%). Unfortunately, with only 
a best enantiomeric excess of 62%, none of these silica-supported catalysts were adequate 
to be applied in continuous flow systems. Early studies on supported catalyst recycling were 
performed, however, they also showed inherent inadequacies.  
 
Despite the lack of very good results, these are very good indicators for what can be 
expected for the polymer-supported 9-picolinamide-cinchona alkaloid derivatives, since 
generally polystyrene-supported systems are more efficient than the silica-supported 
catalysts.333,342-345  
   
 
a Yields determined by 1H NMR. 
b Determined by HPLC on a chiral stationary phase. 
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3. Conclusions and Future Perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“If you would be a real seeker after truth, it is necessary that at least once in your life you 
doubt, as far as possible, all things.” 
Rene Descartes 
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The main objective of this master’s dissertation was the synthesis of the biologically 
active compound used for the treatment of Alzheimer’s disease, Rivastigmine, by a novel 
organocatalytic synthetic pathway. Generally speaking, the key step of the proposed 
synthetic pathway was the enantioselective reduction of ketimine intermediates (precursors 
of Rivastigmine) using a recently developed family of cinchona alkaloid derivatives as 
catalysts.  
We synthesized four previously described 9-picolinamide-cinchona alkaloid derivatives 
and two new catalysts also belonging to this class. After the complete characterization of 
these structures, we can conclude that the synthesis of the desired organocatalysts was 
very successful, considering the good to very good yields that were obtained (of up to 65%).  
Although the synthesis of the carbamate intermediate of Rivastigmine [(3-acetylphenyl)-
N-ethyl-N-methyl carbamate] was more difficult than initially expected, we were able to 
synthesize three different N-benzyl ketimine intermediates and three N-phenyl ketimines, 
derived from both 3’-hydroxyacetophenone and 3’-bromoacetophenone, with excellent 
yields (90-95%).  
When applied in the enantioselective reduction of the prepared ketimine intermediates, 
the six studied organocatalysts revealed very different catalytic properties that also 
depended on the ketimine structure. Indeed, there was a large discrepancy in the results of 
the hydrosilylation of the N-phenyl and N-benzyl ketimines, with values of both yield and 
enantioselectivity being much higher (30-60%) in the N-phenyl ketimines. Regarding the 
catalysts itself, while the N-methylated class of 9-picolinamide-cinchona alkaloids revealed 
to be the most efficient for the enantioselective reduction of ketimines, the N-oxide 
derivatives only afforded the amines in their racemic form. We can conclude that the N-
methylated cinchonidine-derived catalyst 38 (for the N-phenyl ketimine) and quinine-derived 
catalyst 45 (for the N-benzyl ketimine) were the best catalysts in the enantioselective 
reduction of ketimines, regarding enantioselectivity.  
Preliminary studies for the immobilization of 9-picolinamide-cinchona alkaloid derivatives 
were also performed, with the aim of applying the supported catalysts in continuous flow 
systems. Three silica-supported catalysts were prepared and, a preliminary assessment of 
catalyst activity, revealed that (when compared with the homogenous version) there is a loss 
of catalyst efficacy, in the enantioselective reduction of ketimines, when these type of 
materials are used. Immobilization onto a polymer support was more complex and was not 
satisfactorily achieved during the time frame of this project. However, the results obtained 
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for the silica-supported catalysts were very good indicators for what can be expected for the 
polymer-supported 9-picolinamide-cinchona alkaloid derivatives. 
Although we weren’t able to conclude the total synthesis of Rivastigmine within the time 
frame of this project, we believe that the novel proposed synthetic pathway is a very efficient 
route to obtain enantiomerically pure (S)-Rivastigmine. The next step of this project, would 
be the de-protection of the phenolic and the amine groups of the isolated N-phenyl and N-
benzyl amines, in order to perform the carbamate synthesis. 
The elaboration of this master’s dissertation, as well as its rich set of results, opens the 
door for future studies regarding this novel organocatalytic synthetic pathway to 
Rivastigmine. From the organocatalysts used to the structure of the ketimines intermediates, 
there are endless possibilities that can be studied.   
As a continuation of this work, in the near future, it might be interesting to study the effect 
of altering the structure of the picolinamide group, present in the catalyst, and to evaluate 
their activity. Namely, the effect of the counter anion in the N-methylated class of these 
catalysts, which was previously shown to have an influence on catalyst activity.180 Another 
possibility may be the development of a new N-alkylated class of 9-picolinamide-cinchona 
alkaloid catalyst, in order to better understand the influence of an alkyl group (such as 
benzyl), connected to nitrogen of the picolinamide ring, in the transition state. 
The preparation of other ketimines structures, using different primary amines as starting 
materials, is another new objective. The preparation of ketimines with phenyl and benzyl 
derivatives (i.e. with different substituents in the aromatic ring) may lead to a better 
understanding of the influence of ketimine structure on the catalyst activity, allowing us to 
know why there are such discrepancies in their enantioselective reduction results. 
 Taking into consideration the benefits of heterogeneous catalysis previously mentioned, 
we are still focused on the preparation of immobilized picolinamide-derived catalysts, 
specifically on the polymer-supported catalysts.  The application of polymer-supported 9-
picolinamide-cinchona alkaloid derivatives in continuous flow systems may open new 
avenues towards the automated synthesis of biologically active molecules, such as 
Rivastigmine, which would increase the application of these very efficient class of catalysts 
on an industrial scale.  
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4. Experimental Section 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Anybody who has been seriously engaged in scientific work of any kind realizes that over 
the entrance to the gates of the temple of science are written the words: ‘Ye must have 
faith’” 
Max Planck 
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4.1  General Remarks 
 
Cinchonidine, quinine, picolinic acid, 3’-hydroxyacetophenone, 3’-bromoacetophenone 
and all remaining reagents used in this work were purchased from Sigma-Aldrich, Fluka, 
Acros and Alfa Aeser and used as received. All the solvents used in this work were used as 
received, unless otherwise stated. The anhydrous solvents were purified and dried under an 
inert atmosphere using common laboratory techniques.352  
Thin layer chromatography (TLC) was carried out on silica gel 60 F254 pre-coated glass 
plates (0.25 mm thickness) during the immobilization of the catalysts and on aluminium 
backed Kieselgel 60 F254 plates (Merck) for the remaining of the work. TLC plates were 
eluted with the appropriate solvents described in each experimental procedure. Plates were 
visualized by UV light (254 and 366 nm) and/or with phosphomolybdic acid in ethanol after 
heating with a hot air gun. 
Column chromatography was carried out on silica gel (SDS, 70-200 μm) and silica gel 
flash (SDS, 40-63 μm) eluted with the corresponding mobile phase.  
NMR spectra were recorded on a Brucker Avance III instrument (1H: 400 MHz; 13C: 100 
MHz), using CDCl3 and DMSO-d6 as solvents and the signal from the residual non-
deuterated solvent was used as an internal standard. All 1H and 13C NMR chemical shifts 
were reported in ppm (δ). All coupling constants are expressed in Hz.  
Melting points were determined on a Barnstead/Electrothermal 9100 capillary apparatus. 
Enantiomeric excess determinations were performed by High Performance Liquid 
Chromatography (HPLC) in a Hitachi Primaide instrument, equipped with a 1410 series UV 
detector, using Chiracel OD-H as chiral column.  
Unless otherwise stated, all reactions were performed without inert atmosphere 
(nitrogen). 
 
 
4.2 General Procedures 
 
4.2.1 Synthesis of Catalysts 
 
4.2.1.1 Synthesis of (8S,9R)-9-O-mesylquinine (29) 
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According to the method performed by Hoffmann,237 4.015 g of commercial quinine (12.33 
mmol) were dissolved in 50 mL of anhydrous THF, to which then there was added 5.41 mL 
of triethylamine (38.84 mmol). The reaction mixture was cooled to 0ºC in an ice bath and 
2.41 mL of methanesulfonyl chloride (24.66 mmol) was slowly added dropwise. After the 
addition was completed, the mixture was stirred for 2 h at room temperature. 40 mL of a 
saturated solution of sodium bicarbonate was added to the crude mixture and extracted with 
CH2Cl2 (2 x 20 mL). The organic phase was dried with anhydrous MgSO4, filtered and the 
solvent was evaporated under reduced pressure in a rotary evaporator. The crude product 
was purified by silica gel column chromatography (eluted with AcOEt), affording the desired 
product 29 as a yellowish oily solid (3.86 g, 90%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.73 (d, 1H, J=4 Hz, H2’), 7.83 (d, 1H, J=8 Hz, H8’), 
7.60 (t, 1H, J=8 Hz, H7’), 7.51 (t, 1H, J=8 Hz, H6’), 7.42 (bs, 1H, H3’), 7.31 (d, 1H, J=8 Hz, 
H5’), 6.05 (bs, 1H, H9), 5.79-5.75 (m, 1H, H10), 4.99-4.93 (m, 2H, H11), 3.93 (s, 3H, CH3), 
3.30-3.21 (m, 2H, H6, H8), 3.14 (bs, 1H, H2), 2.79-2.75 (m, 5H, H6, H2, CH3), 2.28 (bs, 1H, 
H3), 1.60-1.53 (m, 5H, H7, H5, H4). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 157.03 (C6’), 148.64 (C2’), 144.83 (C10’), 143.01 
(C4’), 139.44 (C10), 131.58 (C9’), 130.76 (C8’), 123.07 (C3’), 120.35 (C7’), 114.39 (C11), 
103.57 (C5’), 59.35 (C9), 56.15 (C8), 56.06 (C-O), 55.70 (C2), 46.67 (C6), 39.49 (C3, C-
mesylate), 28.10 (C7), 27.43 (C4), 25.99 (C5). 
The structure was confirmed by comparison with existing results from the literature.237  
 
4.2.1.2 Synthesis of (8S,9S)-9-azido(9-deoxi)-epi-quinine (30) 
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In a round-bottom flask, 3.86 g of compound 29 (11.10 mmol) was dissolved in 20 mL of 
anhydrous DMF at room temperature and 2 equivalents of NaN3 (1.6 g, 24.66 mmol) were 
added. The mixture was stirred for 24 h at 80-85ºC.240 The reaction was monitored by TLC 
and, after the complete consumption of the substrate, the solvent was removed by 
distillation. H2O (15 mL) was added to the crude mixture and the organic phase was 
extracted with CH2Cl2 (3 x 20 mL), dried with anhydrous MgSO4 and filtered. The solvent 
was evaporated under reduced pressure on a rotary evaporator and the crude product 
purified by silica gel column chromatography, eluted with AcOEt. The desired product 30 
was obtained as a thick orange oil (4.09 g, 89%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.85 (d, 1H, J=4 Hz, H2’), 8.03 (d, 1H, J=8 Hz, H5’), 
7.91 (d, 1H, J=8 Hz, H8’), 7.69 (t, 1H, J=8 Hz, H7’), 7.50 (t, 1H, J=8 Hz, H6’), 7.39 (bs, 1H, 
H3’), 5.75-5.73 (m, 1H, H10), 5.31 (d, 1H, J=10 Hz, H9), 4.98-4.93 (m, 2H, H11), 3.89 (s, 
3H, CH3), 3.32-3.22 (m, 3H, H2, H6, H8), 2.76-2.68 (m, 2H, H6, H2), 2.29 (bs, 1H, H3), 1.65-
1.55 (m, 4H, H7, H5, H4), 0.98-0.85 (m, 1H, H7). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 155.98 (C6’), 150.01 (C2’), 145.97 (C10’), 142.57 
(C4’), 139.98 (C10), 130.89 (C8’), 124.02 (C3’), 121.53 (C7’), 120.89 (C9’), 113.82 (C11), 
108.97 (C5’), 58.98 (C9), 56.42 (C-O) 54.92 (C8), 53.01 (C2), 43.42 (C6), 39.72 (C3), 28.05 
(C7), 27.23 (C4), 25.89 (C5). 
 
4.2.1.3 Synthesis of (8S,9S)-9-amino(9-deoxi)-epi-quinine (31) 
 
 
 
In a round-bottom flask, 4.09 g of organic azide 30 (9.89 mmol) was dissolved in 75 mL 
of anhydrous THF and 6.68 g of triphenylphosphine (25.47 mmol) was slowly added at room 
temperature. The mixture was stirred for 4-6 h at 48-52ºC. After the complete consumption 
of the organic azide, which was monitored by TLC, the reaction mixture was allowed to reach 
room temperature and 1.5 mL of distilled H2O was added, in order to hydrolyze the formed 
intermediate, and left stirring overnight.114 After the hydrolysis step, the excess H2O was 
removed by adding anhydrous MgSO4 to the organic phase. After filtration and solvent 
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evaporated under reduced pressure on a rotary evaporator, the crude product was purified 
by silica gel column chromatography, initially eluted with AcOEt followed by a mixture of 
AcOEt/MeOH/NEt3 (100:2:3). The amine 31 was obtained was a thick yellowish oil (2.62 g, 
82%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.83 (d, 1H, J=4 Hz, H2’), 8.21 (d, 1H, J=8 Hz, H5’), 
8.01 (d, 1H, J=8 Hz, H8’), 7.65 (t, 1H, J=8 Hz, H7’), 7.54 (t, 1H, J=8 Hz, H6’), 7.38 (bs, 1H, 
H3’), 5.79-5.68 (m, 1H, H10), 5.10-4.99 (m, 2H, H11), 4.78 (bs, 1H, H9), 3.93 (s, 3H, CH3), 
3.13 (bs, 1H, H8), 2.81-2.73 (m, 2H, H2, H6), 2.26 (s, 2H, NH2), 2.09 (bs, 1H, H3), 1.67-1.53 
(m, 3H, H7, H5, H4), 1.41-1.35 (m 1H, H5), 0.89-0.71 (m, 1H, H7). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 158.01 (C6’), 150.27 (C2’), 147.88 (C10’), 141.78 
(C4’), 140.03 (C10), 130.97 (C8’), 125.11 (C3’), 122.23 (C7’), 119.67 (C9’), 112.97 (C11), 
109.87 (C5’), 60.10 (C9), 56.04 (C-O), 55.89 (C8), 52.13 (C2), 42.96 (C6), 40.01 (C3), 28.13 
(C7), 26.98 (C4), 25.91 (C5). 
The structure was confirmed by comparison with existing results from the literature.144  
 
4.2.1.4 Synthesis of (8S,9R)-9-O-mesylcinchonidine (32) 
 
 
 
Applying the same procedure as previously described (see 4.2.1.1) using 5.011 g of 
commercial cinchonidine (16.98 mmol), trimethylamine (7.46 mL, 53.49 mmol) and 
methanesulfonyl chloride (2.63 mL, 33.96 mmol), the crude product was purified by silica 
gel column chromatography (eluted with AcOEt), affording the desired product 32 as a white 
solid (5.07 g, 94%). 
 m.p.: 107-108ºC 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.89 (d, 1H, J=4 Hz, H2’), 8.22 (d, 1H, J=8 Hz, H5’), 
8.10 (d, 1H, J=8 Hz, H8’), 7.80 (t, 1H, J=8 Hz, H7’), 7.63 (t, 1H, J=8 Hz, H6’), 7.49 (bs, 1H, 
H3’), 6.62 (bs, 1H, H9), 5.75-5.71 (m, 1H, H10), 5.10-4.99 (m, 2H, H11), 3.51-3.39 (m, 2H, 
H6, H8), 3.15 (bs, 1H, H2), 2.78-2.75 (m, 5H, H6, H2, CH3), 2.34 (bs, 1H, H3), 2.01-1.72 (m, 
5H, H7, H5, H4). 
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13C NMR (100 MHz, CDCl3) δ (ppm) = 150.91 (C2’), 148.64 (C10’), 143.02 (C10), 140.45 
(C4’), 131.56 (C8’), 130.3 (C7’), 127.85 (C6’, C5’), 123.02 (C3’), 116.52 (C11), 59.38 (C9), 
56.42 (C8, C2), 41.02 (C6), 39.25 (C3, C-mesylate), 27.98 (C7), 27.43 (C4), 26.78 (C5). 
The structure was confirmed by comparison with existing results from the literature.237  
 
4.2.1.5 Synthesis of (8S,9S)-9-azido(9-deoxi)-epi-cinchonidine (33) 
 
 
 
Applying the same procedure as previously described (see 4.2.1.2) using 5.07 g of 
compound 32 (15.96 mmol), the crude product was purified by silica gel column 
chromatography (eluted with AcOEt), affording the desired product 33 as a thick orange oil 
(4.84 g, 95%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.92 (d, 1H, J=4 Hz, H2’), 8.32 (d, 1H, J=8 Hz, H5’), 
8.21 (d, 1H, J=8 Hz, H8’), 7.82 (t, 1H, J=8 Hz, H7’), 7.59 (t, 1H, J=8 Hz, H6’), 7.37 (d, 1H, 
J=8 Hz, H3’), 5.77-5.75 (m, 1H, H10), 5.20 (d, 1H, J=10 Hz, H9), 5.00-4.95 (m, 2H, H11), 
3.34-3.21 (m, 3H, H2, H6, H8), 2.95-2.85 (m, 2H, H6, H2), 2.31 (bs, 1H, H3), 1.75-1.60 (m, 
4H, H7, H5, H4), 0.74-0.71 (m, 1H, H7). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 150.21 (C2’), 149.01 (C10’), 142.57 (C10), 141.51 
(C4’), 130.87 (C8’), 126.97 (C6’), 126.13 (C9’), 123.09 (C5’), 120.29 (C3’), 114.28 (C11), 
59.81 (C9), 54.99 (C8), 53.48 (C2), 40.87 (C6), 39.43 (C3), 28.01 (C7), 27.19 (C4), 25.91 
(C5). 
 
4.2.1.6 Synthesis of (8S,9S)-9-amino(9-deoxi)-epi-cinchonidine (34) 
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Applying the same procedure as previously described (see 4.2.1.1) using 4.84 g of 
organic azide 33 (15.16 mmol), the crude product was purified by silica gel column 
chromatography, initially eluted with AcOEt followed by a mixture of AcOEt/MeOH/NEt3 
(100:2:3), affording the desired product 34 as yellowish oil (4 g, 90%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.93 (d, 1H, J=4 Hz, H2’), 8.34 (bs 1H, H5’), 8.20 
(d, 1H, J=8 Hz, H8’), 7.67 (t, 1H, J=8 Hz, H7’), 7.59 (t, 1H, J=8 Hz, H6’), 7.48 (bs, 1H, H3’), 
5.83-5.79 (m, 1H, H10), 5.05-4.77 (m, 2H, H11), 4.76 (bs, 1H, H9), 3.08 (bs, 1H, H8), 2.86-
2.81 (m, 2H, H2, H6), 2.44 (s, 2H, NH2), 2.32 (bs, 1H, H3), 1.65-1.57 (m, 3H, H7, H5, H4), 
1.44-1.41 (m 1H, H5), 0.78-0.72 (m, 1H, H7). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 151.02 (C2’), 149.04 (C10’), 141.87 (C10, C4’), 
130.57 (C8’), 129.13 (C7’), 127.88 (C6’), 126.64 (C9’), 123.76 (C5’), 120.03 (C3’), 114.53 
(C11), 61.94 (C9), 56.28 (C8), 40.86 (C6), 40.02 (C2), 31.03 (C3), 28.18 (C7), 27.54 (C4), 
25.99 (C5). 
The structure was confirmed by comparison with existing results from the literature.144  
 
4.2.1.7 Synthesis of 2-(N-methyl)pyridinium iodide (37) 
 
 
 
Based on the Liebscher procedure,248 4,01 g of picolinic acid (32.49 mmol) were 
dissolved in 40 mL of iPrOH, followed by the addition of 2 equivalents of iodomethane (4.04 
mL, 64.98 mmol). The mixture was stirred for 3 days at 50-55ºC. After that time, the reaction 
mixture was allowed to reach room temperature and the yellow solid that was formed was 
collected by vacuum filtration and washed with cold iPrOH. The desired compound 37 was 
obtained as an amorphous yellow solid (5.86 g, 68%). 
m.p.: 168.9-170.1ºC 
1H NMR (400 MHz, DMSO-d6) δ (ppm) = 9.01 (d, 1H, J=4 Hz, Ar), 8.61 (t, 1H, J=8 Hz, 
Ar), 8.31 (d, 1H, J=8 Hz, Ar), 8.13 (t, 1H, J=8 Hz, Ar), 4.42 (s, 3H, CH3). 
13C NMR (100 MHz, DMSO-d6) δ (ppm) = 161.25 (C=O), 149.12 (Ar), 146.31 (Ar), 138.04 
(Ar), 127.26 (Ar), 124.79 (Ar), 47.89 (CH3). 
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4.2.1.8 Procedure for the synthesis of picolinamides-cinchona alkaloids 
derivatives  
 
 
4.2.1.8.1 Direct condensation method242 
 
Taking the synthesis of compound 36 as an example, in a round-bottom flask, equipped 
with a Dean-Stark apparatus to collect the water formed during the reaction, 0.75 g of amine 
34 (2.56 mmol) was dissolved in 30 mL of anhydrous toluene and then 0.315 g of commercial 
picolinic acid (2.6 mmol) was added, which, at room temperature, formed a white 
suspension. The reaction was stirred at 120-130ºC for 19 h. After this time, the reaction was 
allowed to reach room temperature and the solvent was removed under reduced pressure 
on a rotary evaporator, in order to concentrate the crude organic material as a “spongy” 
orange solid. The crude product was purified by silica gel column chromatography, eluted 
with a mixture of AcOEt/MeOH (4:1), giving the desired product as a “spongy” white solid 
(0.755g, 68%). 
 
4.2.1.8.1.1 Synthesis of (8S,9S)-9-picolinamide(9-deoxi)-epi-
cinchonidine (36) 
 
 
 
m.p.: 85.5-87.1 ºC 
1H NMR (400 MHz, CDCl3) δ (ppm) = 9.18 (bs, 1H, NH), 8.92 (d, 1H, J=4 Hz, H2’), 8.58 
(d, 1H, CH pyridine), 8.48 (d, 1H, CH pyridine), 8.14 (d, 1H, J=8 Hz, H5’), 8.04 (d, 1H, J=8 
Hz, H8’), 7.77-7.74 (m, 2H, H7’, CH pyridine), 7.66 (t, 1H, J=8 Hz, H6’), 7.53 (d, 1H, J=4 Hz, 
H3’), 5.80-5.71 (m, 2H, H10, H9), 5.06-4.97 (m, 2H, H11), 3.41-3.31 (m, 2H, H6, H2), 3.20 
(bs, 1H, H8), 2.95-2.79 (m, 2H, H6, H2), 2.22 (bs, 1H, H3), 1.64-1.58 (m, 3H, H4, H5, H7), 
1.30-1.25 (m, 1H, H5), 0.89-0.86 (m, 1H, H7). 
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13C NMR (100 MHz, CDCl3) δ (ppm) = 164.47 (C=O), 150.30 (pyridine), 149.83 (C2’), 
148.73 (C10’), 148.41 (pyridine), 146.25 (C4’), 140.96 (pyridine), 137.33 (C10), 130.58 
(C8’), 129.40 (C7’), 127.46 (C6’), 127.16 (C9’), 126.32 (pyridine), 123.49 (pyridine), 122.47 
(C5’), 119.69 (C3’), 115.02 (C11), 60.52 (C9), 59.86 (C8), 55.72 (C2), 41.08 (C6), 39.28 
(C3), 27.58 (C7), 27.35 (C4), 26.12 (C5). 
The structure was confirmed by comparison with existing results from the literature.180 
 
4.2.1.8.1.2 Synthesis of (8S,9S)-9-[2-(N-methyl)pyridinium]-(9-deoxi)-
epi-cinchonidine iodide (38)  
 
 
 
Applying the direct condensation method described above (see 4.2.1.8.1), compound 38 
was synthesized from 0.512 g of amine 34 (1.74 mmol) and 1.5 equivalents of 2-(N-
methyl)pyridinium iodide 37 (0.663 g, 2.5 mmol). The crude product was purified by silica 
gel column chromatography, eluted with a mixture of AcOEt/MeOH (4:1), giving the desired 
product as an orange “oily” solid (0.545 g, 58%). 
1H NMR (400 MHz, DMSO-d6) δ (ppm) = 9.21 (bs, 1H, NH), 8.86 (d, 1H, J=4 Hz, H2’), 
8.67 (d, 1H, CH pyridine), 8.48 (d, 1H, CH pyridine), 8.02 (d, 1H, J=8 Hz, H5’), 7.93 (d, 1H, 
J=8 Hz, H8’), 7.78 (d, 1H, J=8 Hz, H7’), 7.69 (t, 1H, J=8 Hz, H6’), 7.61-7.58 (m, 2H, H3’, CH 
pyridine), 7.48-7.42 (m, 1H, CH pyridine), 5.83-5.75 (m, 2H, H10, H9), 5.04-4.93 (m, 2H, 
H11), 3.32 (m, 6H, H8, H6, H2, N-CH3), 2.87-2.81 (m, 2H, H6, H2), 2.27 (bs, 1H, H3), 1.57 
(bs, 3H, H4, H5, H7), 1.40 (bs, 1H, H5), 0.90 (bs, 1H, H7). 
13C NMR (100 MHz, DMSO-d6) δ (ppm) = 163.14 (C=O), [149.52, 148.56, 142.03, 137.90, 
135.23, 129.77, 129.11, 128.79, 128.38, 126.73, 126.66, 124.64, 121.83, 114.35 (14C 
aromatics, 2C vinylics)], [57.89, 55.04, 49.13, 39.62, 27.08, 25.64 (C aliphatic)]. 
The structure was confirmed by comparison with existing results from the literature.180 
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4.2.1.8.2 Coupling method by the formation of a mixed anhydride 
intermediate249  
 
 
Taking the synthesis of compound 36 as an example, in a round-bottom flask, 0.142 g of 
commercial picolinic acid was dissolved in 20 mL of anhydrous THF and 0.199 mL of 
triethylamine (1.43 mmol) was added.  The reaction was stirred for 10-15 minutes at room 
temperature. In a separate two neck round-bottom flask, 0.132 mL of isobutyl chloroformate 
(1.02 mmol) was dissolved in 10 mL of anhydrous THF, under inert atmosphere, and the 
reaction mixture was cooled in an ice bath. The picolinic acid and triethylamine mixture was 
then slowly added to the isobutyl chloroformate, during which the formation of a white 
precipitate (triethylammonium chloride) was observed. After completing the addition, the 
reaction was stirred at room temperature for 2 hours. Then 0.3 g of amine 34 (1.02 mmol), 
previously diluted in 5 ml of THF was added, and the reaction was stirred for another hour. 
After the consumption of the formed intermediate (mixed anhydride) by TLC, the reaction 
was quenched with the addition of 10 mL of H2O and extracted with CH2Cl2 (3 x 10 mL). The 
collected organic phase was dried with anhydrous MgSO4, filtered and the solvent was 
evaporated under reduced pressure on a rotary evaporator. The crude product purified by 
silica gel column chromatography, initially eluted with AcOEt followed by a mixture of 
AcOEt/MeOH (95:5), giving the desired compound as a “spongy” white solid (0.171g, 42%). 
 
 
4.2.1.8.2.1 Synthesis of (8S,9S)-9-picolinamide(9-deoxi)-epi-
cinchonidine (36) 
 
 
 
The structure was confirmed by comparison with existing results from the literature.180 
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4.2.1.8.2.2 Synthesis of (8S,9S)-9-[2-(N-methyl)pyridinium]-(9-deoxi)-
epi-cinchonidine iodide (38) 
 
 
 
 
 
Applying the mixed anhydride method described above (see 4.2.1.8.2), compound 38 
was synthesized from 0.300 g of amine 34 (1.02 mmol), 2-(N-methyl)pyridinium iodide 37 
(0.270 g, 1.02 mmol), NEt3 (0.199 mL, 1.43 mmol) and isobutyl chloroformate (0.132 mL, 
1.02 mmol) in THF. The crude product was purified by silica gel column chromatography, 
initially eluted with AcOEt followed by a mixture of AcOEt/MeOH (95:5), giving the desired 
product as an orange “oily” solid (0.265g, 48%). 
The structure was confirmed by comparison with existing results from the literature.180 
 
 
4.2.1.8.2.3 Synthesis of (8S,9S)-9-[2-(N-oxide)picolinamide]-(9-deoxi)-
epi-cinchonidine (40) 
 
 
 
Applying the mixed anhydride method described above (see 4.2.1.8.2), compound 40 
was synthesized from 0.300 g of amine 34 (1.02 mmol), picolinic acid N-oxide (0.142 g, 1.02 
mmol), NEt3 (0.199 mL, 1.43 mmol) and isobutyl chloroformate (0.132 mL, 1.02 mmol) in 
THF. The crude product was purified by silica gel column chromatography, eluted with a 
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mixture of AcOEt/MeOH (95:5), giving the desired product as an yellowish “oily” solid (0.233 
g, 55%). 
1H NMR (400 MHz, DMSO-d6) δ (ppm) = 8.88 (d, 1H, J=4 Hz, H2’), 8.46 (d, 1H, CH 
pyridine), 8.13 (d, 1H, CH pyridine), 8.03 (d, 1H, J=8 Hz, H5’), 7.86 (d, 1H, J=8 Hz, H8’), 
7.76 (d, 1H, J=8 Hz, H7’), 7.68 (t, 1H, J=8 Hz, H6’), 6.96-6.93 (m, 2H, H3’, CH pyridine), 
6.79-6.42 (m, 1H, CH pyridine), 5.82-5.76 (m, 1H, H10), 5.01-4.91 (m, 2H, H11), 4.27-4.24 
(m, 1H, H9), 3.86-3.84 (m, 2H, H6, H2), 3.64 (bs, 1H, H8), 3.19-3.11 (m, 2H, H6, H2), 2.32 
(bs, 1H, H3), 1.75-1.73 (m, 3H, H4, H5, H7), 1.50 (bs, 1H, H5), 0.93-0.81 (m, 1H, H7). 
13C NMR (100 MHz, DMSO-d6) δ (ppm) = 163.23 (C=O), [154.75, 150.26, 147.89, 146.84, 
142.09, 139.08, 138.56, 129.75, 129.09, 126.65, 123.85, 116.92, 114.16, 110.42 (14C 
aromatics, 2C vinylics)], [73.16, 67.15, 64.76, 55.20, 27.28, 18.84 (C aliphatic)]. 
 
4.2.1.8.2.4 Synthesis of (8S,9S)-9-picolinamide(9-deoxi)-epi-quinine (44) 
 
 
 
Applying the mixed anhydride method described above (see 4.2.1.8.2), compound 44 
was synthesized from 0.300 g of amine 31 (0.928 mmol), commercial picolinic acid (0.129 
g, 0.928 mmol), NEt3 (0.181 mL, 1.30 mmol) and isobutyl chloroformate (0.120 mL, 0.928 
mmol) in THF. The crude product was purified by silica gel column chromatography, initial 
eluted with AcOEt followed by a mixture of AcOEt/MeOH (95:5), giving the desired product 
as a white “oily” solid (0.159 g, 40%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.98 (bs, 1H, NH), 8.76 (d, 1H, J=4 Hz, H2’), 8.54 
(d, 1H, CH pyridine), 8.48 (d, 1H, CH pyridine), 8.09 (d, 1H, J=8 Hz, H5’), 8.02 (d, 1H, J=8 
Hz, H8’), 7.78-7.74 (m, 2H, H7’, CH pyridine), 7.45 (d, 1H, J=4 Hz, CH pyridine), 7.38 (d, 
1H, J=4 Hz, H3’), 5.84-5.76 (m, 2H, H10, H9), 5.34 (bs, 1H, H11), 5.10-5.05 (m, 2H, H11), 
4.00 (s, 3H, CH3), 3.49-3.38 (m, 2H, H6, H2), 3.23 (bs, 1H, H8), 2.81-2.69 (m, 2H, H6, H2), 
2.31 (bs, 1H, H3), 1.63-1.58 (m, 3H, H4, H5, H7), 1.38-1.25 (m, 1H, H5), 0.89-0.86 (m, 1H, 
H7). 
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13C NMR (100 MHz, CDCl3) δ (ppm) = 164.12 (C=O), 157.96 (pyridine), 149.77 (C2’), 
148.30 (C10’), 147.60 (pyridine), 144.87 (C4’), 141.41 (pyridine), 137.22 (C10), 131.87 
(C8’), 130.03 (C7’), 126.31 (C6’), 122.41 (C9’), 122.10 (pyridine), 121.84 (pyridine), 119.64 
(C5’), 114.52 (C3’), 101.66 (C11), 60.41 (C9), 56.11 (C8), 55.64 (C2), 51.14 (C-O), 41.29 
(C6), 39.28 (C3), 27.37 (C7), 27.23 (C4), 26.59 (C5). 
The structure was confirmed by comparison with existing results from the literature.180 
 
4.2.1.8.2.5 Synthesis of (8S,9S)-9-[2-(N-methyl)pyridinium]-(9-deoxi)-
epi-quinine iodide (45) 
 
 
 
Applying the mixed anhydride method described above (see 4.2.1.8.2), compound 45 
was synthesized from 0.300 g of amine 31 (0.928 mmol), 2-(N-methyl)pyridinium iodide 37 
(0.246 g, 0.928 mmol), NEt3 (0.181 mL, 1.30 mmol) and isobutyl chloroformate (0.120 mL, 
0.928 mmol) in THF. The crude product was purified by silica gel column chromatography, 
eluted with a mixture of AcOEt/MeOH (95:5), giving the desired product as an yellowish “oily” 
solid (0.238 g, 45%). 
1H NMR (400 MHz, DMSO-d6) δ (ppm) = 9.22 (bs, 1H, NH), 8.72 (d, 1H, J=6 Hz, H2’), 
8.62 (d, 1H, CH pyridine), 8.45 (d, 1H, CH pyridine), 8.05 (d, 1H, J=8 Hz, H5’), 7.95 (d, 1H, 
J=8 Hz, H8’), 7.82 (d, 1H, J=8 Hz, H7’), 7.60-7.58 (m, 2H, H3’, CH pyridine), 7.43-7.41 (m, 
1H, CH pyridine), 5.94-5.74 (m, 2H, H10, H9), 5.10-5.00 (m, 2H, H11), 3.93 (s, 3H, CH3), 
3.43 (m, 6H, H8, H6, H2, N-CH3), 2.85-2.80 (m, 2H, H6, H2), 2.24 (bs, 1H, H3), 1.58 (bs, 
3H, H4, H5, H7), 1.26 (bs, 1H, H5), 0.86 (bs, 1H, H7). 
13C NMR (100 MHz, DMSO-d6) δ (ppm) = 157.43 (C=O), [149.52, 148.53, 147.73, 144.12, 
142.13, 137.97, 131.39, 129.47, 128.11, 126.83, 124.98, 122.09, 121.36, 115.11 (14C 
aromatics, 2C vinylics)], [58.15, 55.67, 49.91, 30.76, 26.93, 26.53 (C aliphatic)]. 
The structure was confirmed by comparison with existing results from the literature.180 
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4.2.1.8.2.6 Synthesis of (8S,9S)-9-[2-(N-oxide)picolinamide]-(9-deoxi)-
epi-quinine (43) 
 
 
 
Applying the mixed anhydride method described above (see 4.2.1.8.2), compound 43 
was synthesized from 0.300 g of amine 31 (0.928 mmol), picolinic acid N-oxide (0.129 g, 
0.928 mmol), NEt3 (0.181 mL, 1.30 mmol) and isobutyl chloroformate (0.120 mL, 0.928 
mmol) in THF. The crude product was purified by silica gel column chromatography, eluted 
with a mixture of AcOEt/MeOH (95:5), giving the desired product as an orange “oily” solid 
(0.305 g, 74%). 
1H NMR (400 MHz, DMSO-d6) δ (ppm) = 8.71 (d, 1H, J=4 Hz, H2’), 7.94 (d, 1H, CH 
pyridine), 7.70 (d, 1H, CH pyridine), 7.49 (d, 1H, J=8 Hz, H5’), 7.43 (d, 2H, J=8 Hz, H8’, H3’), 
7.34 (d, 1H, J=8 Hz, H7’), 6.31 (d, 1H, CH pyridine), 6.14 (d, 1H, CH pyridine), 5.90-5.86 (m, 
2H, H9, H10), 5.27 (m, 1H, H11), 5.03-4.95 (m, 1H, H11), 3.92 (s, 3H, CH3), 3.67-3.64 (m, 
2H, H6, H2), 3.35 (bs, 1H, H8), 2.69-2.62 (m, 2H, H6, H2), 2.24 (bs, 1H, H3), 1.76-1.61 (m, 
3H, H4, H5, H7), 1.23-1.15 (m, 1H, H5), 0.85-0.83 (m, 1H, H7). 
13C NMR (100 MHz, DMSO-d6) δ (ppm) = 162.24 (C=O), [157.15, 155.85, 147.48, 146.02, 
143.85, 142.03, 140.82, 135.32, 131.12, 121.10, 119.87, 11468, 104.69, 102.09 (14C 
aromatics, 2C vinylics)], [69.68, 55.39, 55.14, 27.47, 26.10, 18.69 (C aliphatic)]. 
 
4.2.2 Synthesis of Rivastigmine Precursors  
 
4.2.2.1 Synthesis of (3-acetylphenyl)-N-ethyl-N-methyl carbamate (48) 
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Based on existing methods in the literature,353,354 500 mg of carbonyl di-imidazole (3.1 
mmol) and 422 mg of 3’-hydroxyacetophenone (3.1 mmol) were dissolved in 10 mL of 
anhydrous dicloromethane. The reaction was stirred for 1 h at room temperature and, after 
that time, 291 μL of ethylmethylamine (3.4 mmol) was added to the mixture. The reaction 
was stirred for another 24 hours at room temperature, under nitrogen atmosphere. The 
solvent was evaporated under reduced pressure on a rotary evaporator and the crude 
product purified by silica gel column chromatography eluted with CH2Cl2. The desired 
product 48 was obtained as a colorless oil (103 mg, 15%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.41 (m, 1H, Ar), 7.26 (m, 1H, Ar), 7.03 (m, 1H, Ar), 
6.87 (m, 1H, Ar), 3.01 (bs, 2H, CH2), 2.63 (bs, 3H, CH3), 2.15 (s, 3H, CH3), 0.85 (bs, 3H, 
CH3) 
13C NMR (100 MHz, CDCl3) δ (ppm) = 198.03 (C=O), 154.56 (C=O), 151.92 (Ar), 137.98 
(Ar), 129.67 (Ar), 127.08 (Ar), 125.24 (Ar), 121.67 (Ar), 44.41 (CH2), 33.97 (CH3), 26.85 
(CH3), 12.97 (CH3).  
 
 
4.2.2.2 Synthesis of N-ethyl-N-methyl-imidazole-1-carboxamide (51) 
 
 
 
In a round-bottom flask, 0.145 mL ethylmethylamine (1.7 mmol), 1.30 g of carbonyl di-
imidazole (8.5 mmol), 52.7 mg of CF3(SO3)3Yb (0.085 mmol) and 10 mL of anhydrous THF 
were added. The reaction was stirred for 24h at 40ºC and, after that time, the reaction was 
allowed to reach room temperature.305 CH2Cl2 (2 mL) was added to make precipitate the 
catalyst, which was then filtered under vacuum. The filtrate was diluted with CH2Cl2 (20 mL), 
washed twice with a 2% solution of citric acid, dried over anhydrous MgSO4, filtered and 
evaporated under reduced pressure in a rotary evaporator, giving the desired product as a 
colorless oil (125 mg, 48%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.81 (bs, 1H, Ar), 7.17 (bs, 1H, Ar), 7.01 (bs, 1H, 
Ar), 3.38-3.33 (q, 2H, J=12 Hz, CH2), 2.96 (s, 3H, CH3), 1.16 (t, 3H, J=9.4 Hz, CH3). 
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13C NMR (100 MHz, CDCl3) δ (ppm) = 151.83 (C=O), 136.93 (Ar), 129.26 (Ar), 118.08 
(Ar), 45.13 (CH2), 35.42 (CH3), 12.30 (CH3). 
 
4.2.2.3 Synthesis of 3’-benzyloxyacetophenone (54) 
 
 
 
In a two-necked round-bottom flask, 2 g of 3’-hydroxyacetophenone (14.69 mmol) was 
dissolved in 20 mL of anhydrous THF. The reaction mixture was cooled to 0ºC in an ice bath 
and 0.388 g of NaH was slowly added. After stirring for a few minutes, the reaction changed 
aspect acquiring a brownish coloration and 1.92 mL of benzyl bromide was added. The 
reaction was stirred at 60ºC for 18 h. H2O (20 mL) was added to the crude mixture and the 
organic phase was extracted with CH2Cl2 (3 x 20 mL), dried with anhydrous MgSO4 and 
filtered. The solvent was evaporated under reduced pressure on a rotary evaporator and the 
crude product purified by silica gel column chromatography, initially eluted with hexane and 
then with a mixture of Hex/AcOEt (95/5). The desired product 54 was obtained as an orange 
oil (1.88 g, 57%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.60 (bs, 1H, Ar), 7.56 (d, 1H, J=8 Hz, Ar), 7.46 (d, 
1H, J=8 Hz, Ar), 7.43-7.35 (m, 4H, Ar), 7.19 (d, 1H, J=8 Hz, Ar), 5.11 (s, 2H, CH2), 2.59 (s, 
3H, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 197.88 (C=O), 159.02 (C-O), 138.56 (Cq), 136.58 
(Cq), 129.68 (Ar), 128.69 (2 Ar), 128.18 (Ar), 127.61 (2 Ar), 121.37 (Ar), 120.30 (Ar), 113.64 
(Ar), 70.20 (CH2), 26.75 (CH3). 
 
4.2.2.4 Synthesis of 3’-methyloxyacetophenone (58) 
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Applying the same procedure as previously described (see 4.2.2.3) using 2 g of 3’-
hydroxyacetophenone (14.69 mmol), NaH (388 mg, 16.16 mmol) and iodomethane (1 mL, 
16.16 mmol), the crude product was purified by silica gel column chromatography, initially 
eluted with hexane followed by a mixture of Hex/AcOEt (95/5), affording the desired product 
58 as orange oil (1.35 g, 61%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.46 (d, 1H, J=8 Hz, Ar), 7.41 (bs, 1H, Ar), 7.29 (t, 
1H, J=8 Hz, Ar), 7.04 (d, 1H, J=8 Hz, Ar), 3.77 (s, 3H, CH3), 2.52 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 197.71 (C=O), 159.65 (C-O), 138.31 (Cq), 129.43 
(Ar), 120.94 (Ar), 119.35 (Ar), 112.25 (Ar), 55.19 (CH3), 26.51 (CH3). 
 
 
4.2.2.5 General procedure for the synthesis of prochiral ketimines213 
 
4.42 mmol of ketone, 8.84 mmol of amine, anhydrous toluene (10 mL) and 4 Å molecular 
sieves were introduced in a two-necked round-bottom flask under nitrogen atmosphere. The 
reaction mixture was stirred for 18 h at 60ºC. After cooling to room temperature, the crude 
reaction was filtered and washed with CH2Cl2 (previously treated with sodium bicarbonate). 
The solvent was evaporated under reduced pressure on a rotary evaporator and the crude 
product used without further purification.   
 
4.2.2.5.1 Synthesis of N-(1-(3-(benzyloxy)phenyl)ethylidene)benzylamine 
(55) 
 
 
 
Applying the procedure described above (see 4.2.2.5), ketimine 55 was synthetized 
starting from 1 g of compound 54 (4.42 mmol) and 0.965 mL of benzylamine (8.84 mmol), 
as a yellow oil (1.29 g, 91%) 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.64 (bs, 1H, Ar), 7.50-7.46 (m, 2H, Ar), 7.44-7.30 
(m, 10H, Ar), 7.06 (bs, 1H, Ar), 5.15 (s, 2H, CH2), 4.79 (s, 2H, CH2), 2.35 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 165.74 (C=N), 158.84 (C-O), 142.61 (Cq), 140.57 
(Cq), 137.04 (Cq), 129.25 (Ar), 128.63 (2 Ar), 128.44 (2 Ar), 128.02 (Ar), 127.74 (2 Ar), 127.64 
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(2 Ar), 126.61 (Ar), 119.64 (Ar), 116.30 (Ar), 113.13 (Ar), 70.08 (CH2), 55.70 (CH2), 15.98 
(CH3). 
 
4.2.2.5.2 Synthesis of N-(1-(3-(benzyloxy)phenyl)ethylidene)aniline (57) 
 
 
 
Applying the procedure described above (see 4.2.2.5), ketimine 57 was synthetized 
starting from 1 g of compound 54 (4.42 mmol) and 0.806 mL of aniline (8.84 mmol), as a 
yellowish oil (1.21 g, 90%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.73 (bs, 1H, Ar), 7.57 (d, 1H, J=8 Hz, Ar), 7.51-
7.47 (m, 2H, Ar), 7.45-7.37 (m, 7H, Ar), 6.84 (d, 2H, J=8 Hz, Ar), 6.71 (d, 1H, J=8 Hz, Ar), 
5.16 (s, 2H, CH2), 2.25 (s, 3H, CH3).  
13C NMR (100 MHz, CDCl3) δ (ppm) = 165.39 (C=N), 159.05 (C-O), 151.69 (Cq), 141.02 
(Cq), 135.96 (Cq), 129.46 (Ar), 129.07 (2 Ar), 128.69 (2 Ar), 128.11 (Ar), 127.69 (2 Ar), 123.38 
(Ar), 120.38 (Ar), 119.46 (2 Ar), 117.95 (Ar), 133.16 (Ar), 70.25 (CH2), 17.61 (CH3). 
 
4.2.2.5.3 Synthesis of N-(1-(3-methoxyphenyl)ethylidene)benzylamine (59) 
 
 
 
Applying the procedure described above (see 4.2.2.5), ketimine 59 was synthetized 
starting from 1 g of compound 58 (6.66 mmol) and 1.45 mL of benzylamine (13.32 mmol), 
as a dark yellow oil (1.48 g, 92%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.56-7.49 (m, 4H, Ar), 7.44-7.31 (m, 4H, Ar), 7.01 
(bs, 1H, Ar), 4.80 (s, 2H, CH2), 3.88 (s, 3H, CH3), 2.35 (s, 3H, CH3). 
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13C NMR (100 MHz, CDCl3) δ (ppm) = 169.48 (C=N), 159.58 (C-O), 142.54 (Cq), 140.52 
(Cq), 129.15 (Ar), 128.37 (2 Ar), 127.63 (2 Ar), 126.53 (Ar), 119.33 (Ar), 115.41 (Ar), 112.01 
(Ar), 55.27 (CH2), 15.92 (CH3). 
 
4.2.2.5.4 Synthesis of N-(1-(3-methoxyphenyl)ethylidene)aniline (60) 
 
 
 
Applying the procedure described above (see 4.2.2.5), ketimine 60 was synthetized 
starting from 1 g of compound 58 (6.66 mmol) and 1.21 mL of aniline (13.32 mmol), as an 
orange oil (1.42 g, 94%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.64 (bs, 1H, Ar), 7.55 (d, 1H, J=8 Hz, Ar), 7.39 (t, 
3H, J=8 Hz, Ar), 7.06 (d, 1H, J=8 Hz, Ar), 6.84 (d, 2H, J=8 Hz, Ar), 6.70 (d, 1H, J=8 Hz, Ar), 
3.80 (s, 3H, CH3), 2.25 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 165.36 (C=N), 159.75 (C-O), 151.68 (Cq), 140.97 
(Cq), 129.37 (Ar), 129.04 (2 Ar), 133.32 (Ar), 119.91 (Ar), 119.68 (2 Ar), 116.89 (Ar), 111.87 
(Ar), 55.46 (CH3), 17.57 (CH3). 
 
4.2.2.5.5 Synthesis of N-(1-(3-bromophenyl)ethylidene)benzylamine (63) 
 
 
 
Applying the procedure described above (see 4.2.2.5), ketimine 63 was synthetized 
starting from 332 μL of 3’-bromoacetophenone (2.51 mmol) and 548 μL of benzylamine (5.02 
mmol), as a colorless oil (0.688 g, 95%). 
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1H NMR (400 MHz, CDCl3) δ (ppm) = 8.09 (bs, 1H, Ar), 7.82 (d, 1H, J=8 Hz, Ar), 7.55 (d, 
1H, J=8 Hz, Ar), 7.48 (bs, 2H, Ar), 7.43-7.39 (t, 2H, J=8 Hz, Ar), 7.33-7.28 (m, 2H, Ar), 4.76 
(s, 2H, CH2), 2.32 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 164.43 (C=N), 142.93 (Cq), 140.20 (Cq), 132.50 
(Ar), 129.84 (Ar), 129.75 (Ar), 128.46 (Ar), 127.71 (2 Ar), 126.70 (Ar), 125.37 (Ar), 122.61 
(C-Br), 55.81 (CH2), 15.78 (CH3). 
 
4.2.2.5.6 Synthesis of N-(1-(3-bromophenyl)ethylidene)aniline (64) 
 
 
 
Applying the procedure described above (see 4.2.2.5), ketimine 64 was synthetized 
starting from 664 μL of 3’-bromoacetophenone (5.02 mmol) and 916 μL of aniline (10.05 
mmol), as a colorless oil (1.3 g, 94%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 8.22, (bs, 1H, Ar), 7.90 (d, 1H, J=8 Hz, Ar), 7.61 
(d, 1H, J=8 Hz, Ar), 7.40 (t, 2H, J=8 Hz, Ar), 7.33 (t, 1H, J=8 Hz, Ar), 7.20-7.13 (m, 1H, Ar), 
6.83 (t, 2H, J=6 Hz, Ar), 2.23 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 164.02 (C=N), 151.16 (Cq), 141.37 (Cq), 133.29 
(Ar), 130.25 (Ar), 129.88 (Ar), 129.02 (2 Ar), 125.80 (Ar), 123.52 (Ar), 119.25 (2 Ar), 115.04 
(C-Br), 17.29 (CH3). 
 
4.3 Hydrosilylation of Ketimines 
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Enantioselective reduction of ketimines with organocatalysts:175 
In a 10 mL round-bottom flask, the ketimine (0.32 mmol) and 10 mol% of organocatalyst 
was dissolved in 2 mL of anhydrous CH2Cl2, under nitrogen atmosphere. The mixture was 
cooled to 0ºC and stirred for 15 min, after which 3.5 equivalents of HSiCl3 (1.11 mmol) was 
added. The reaction mixture was allowed to reach room temperature and stirred for 18 h, 
after which the mixture was quenched with a solution of NaOH 10% until a basic pH was 
reached. The organic phase was extracted with CH2Cl2 (3 x 10 mL), dried with anhydrous 
MgSO4 and filtered. The solvent was evaporated under reduced pressure on a rotary 
evaporator and the crude product purified by silica gel column chromatography, eluted with 
a mixture of Hex/AcOEt (95:5), giving the desired amine.  
 
Procedure for racemic chiral amines: 
In a 10 mL round-bottom flask, the ketimine (0.32 mmol) and 5 equivalents of DMF (1.65 
mmol) was dissolved in 2 mL of anhydrous CH2Cl2, under nitrogen atmosphere. The mixture 
was cooled to 0ºC and stirred for 15 min, after which 3.5 equivalents of HSiCl3 (1.11 mmol) 
was added. The reaction mixture was allowed to reach room temperature and stirred for 18 
h, after which the mixture was quenched with a solution of NaOH 10% until a basic pH was 
reached. The organic phase was extracted with CH2Cl2 (3 x 10 mL), dried with anhydrous 
MgSO4 and filtered. The solvent was evaporated under reduced pressure on a rotary 
evaporator and the crude product purified by silica gel column chromatography, eluted with 
a mixture of Hex/AcOEt (95:5), giving the desired amine.  
 
4.3.1 Synthesis of N-(1-(3-(benzyloxy)phenyl)ethyl)aniline (65) 
 
 
 
The desired product was obtained as a yellowish oil. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.49 (d, 2H, J=8 Hz, Ar), 7.44 (t, 2H, J=8 Hz, Ar), 
7.39 (d, 2H, J=8 Hz, Ar), 7.31 (t, 2H, J=4 Hz, Ar), 7.17 (t, 2H, J=8 Hz, Ar), 7.10 (bs, 1H, Ar), 
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7.04 (d, 1H, J=4 Hz, Ar), 6.91 (d, 1H, J=8 Hz, Ar), 6.73 (t, 1H, J=8 Hz, Ar), 6.69 (d, 1H, J=8 
Hz, Ar), 5.09 (s, 2H, CH2), 4.41 (q, 1H, J=8 Hz, CH), 1.57 (d, 3H, J=8 Hz, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 159.26 (C-O), 147.27 (Cq), 137.0 (Cq), 129.79 (Ar), 
129.19 (2 Ar), 128.65 (2 Ar), 128.04 (2 Ar), 127.72 (2 Ar), 118.61 (Ar), 117.45 (Ar), 113.47 
(Ar), 113.02 (Ar), 112.71 (Ar), 70.06 (CH2), 53.66 (CH), 25.04 (CH3). 
HPLC: Chiracel OD-H column, hexane/2-propanol (98:2), flow rate: 0.8 mL/min, 
wavelength detector at 254 nm, tR= 14.38 min (S), tR= 18.82 (R). 
 
4.3.2 Synthesis of N-(1-(3-methoxyphenyl)ethyl)aniline (66) 
 
 
 
The desired product was obtained as a pale orange oil. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.31 (t, 1H, J=8 Hz, Ar), 7.17 (t, 1H, J=8 Hz, Ar), 
7.05 (bs, 1H, Ar), 7.02 (bs, 1H, Ar), 6.34 (d, 1H, J=8 Hz, Ar), 6.73 (t, 1H, J=8 Hz, Ar), 6.59 
(d, 2H, J=8 Hz, Ar), 4.51 (q, 1H, J=8 Hz, CH), 3.83 (s, 3H, CH3), 1.57 (d, 3H, J=8 Hz, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 159.95 (C-O), 147.30 (Cq), 147.20 (Cq), 129.70 
(Ar), 129.12 (Ar), 118.24 (Ar), 117.31 (Ar), 113.37 (2 Ar), 111.99 (Ar), 111.72 (Ar), 55.14 ( 
CH3), 53.56 (CH2), 25.00 (CH3). 
HPLC: Chiracel OD-H column, hexane/2-propanol (98:2), flow rate: 0.8 mL/min, 
wavelength detector at 254 nm, tR= 15.44 min (S), tR= 17.91 min (R). 
 
4.3.3 Synthesis of N-(1-(3-bromophenyl)ethyl)aniline (67) 
 
 
 
The desired product was obtained as a colorless oil. 
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1H NMR (400 MHz, CDCl3) δ (ppm) = 7.57 (bs, 1H, Ar), 7.39 (d, 1H, J=8 Hz, Ar), 7.33 (d, 
1H, J=4 Hz, Ar), 7.21 (t, 1H, J=8 Hz, Ar), 7.15 (t, 2H, J=8 Hz, Ar), 6.72 (t, 1H, J=8 Hz, Ar), 
6.53 (d, 2H, J=8 Hz, Ar), 4.45 (q, 1H, J=8 Hz, CH), 1.52 (d, 3H, J=8 Hz, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 147.96 (Cq), 146.93 (Cq), 130.37 (Ar), 130.10 (Ar), 
129.23 (2 Ar), 129.03 (Ar), 124.57 (Ar), 122.89 (C-Br) 117.67 (Ar), 113.40 (2 Ar), 53.30 (CH), 
25.13 (CH3). 
HPLC: Chiracel OD-H column, hexane/2-propanol (90:10), flow rate: 0.8 mL/min, 
wavelength detector at 254 nm, tR= 17.07 min (S), tR= 21.97 min (R). 
 
4.3.4 Synthesis of N-(1-(3-(benzyloxy)phenyl)ethyl)benzylamine (68) 
 
 
 
The desired product was obtained as a yellow oil. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.97 (d, 2H, J=8 Hz, Ar), 7.49 (t, 2H, J=8 Hz, Ar), 
7.45-7.35 (m, 7H, Ar), 7.17 (bs, 1H, Ar), 7.08 (d, 1H, J=8 Hz, Ar), 7.00 (d, 1H, J=8 Hz, Ar), 
5.18 (s, 2H, CH2), 3.91 (q, 1H, J=8 Hz, CH), 3.80-3.69 (m, 2H, CH2), 1.48 (d, 3H, J=8 Hz, 
CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 159.13 (Cq), 147.50 (Cq), 140.69 (Cq) 137.15 (Cq), 
129.51 (Ar), 128.58 (2 Ar), 128.42 (2 Ar), 128.39 (2 Ar), 128.17 (Ar), 127.96 (2 Ar), 126.87 
(Ar), 119.43 (Ar), 113.23 (Ar), 113.13 (Ar), 69.62 (CH2), 57.53 (CH), 51.70 (CH2), 24.58 
(CH3). 
HPLC: Chiracel OD-H column, hexane/2-propanol (99:1), flow rate: 0.8 mL/min, 
wavelength detector at 254 nm, tR= 15.52 min (R), tR= 23.23 min (S). 
 
4.3.5 Synthesis of N-(1-(3-methoxyphenyl)ethyl)benzylamine (69) 
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The desired product was obtained as a yellowish oil. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.39-7.29 (m, 6H, Ar), 7.00 (d, 2H, J=8 Hz, Ar), 
6.86 (d, 1H, J=8 Hz, Ar), 4.29 (q, 1H, J=8 Hz, CH), 3.86 (s, 3H, CH3), 3.70 (q, 2H, J=8 Hz, 
CH2), 1.42 (d, 3H, J=8 Hz, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 159.89 (Cq), 147.38 (Cq), 140.62 (Cq), 129.47 (Ar), 
128.41 (2 Ar), 128.38 (2 Ar), 126.88 (Ar), 119.12 (Ar), 112.27 (Ar), 112.22 (Ar), 57.55 (CH), 
56.12 (CH3), 51.68 (CH2), 24.53 (CH3). 
HPLC: Chiracel OD-H column, hexane/2-propanol (98:2), flow rate: 0.8 mL/min, 
wavelength detector at 254 nm, tR= 8.79 min (R), tR= 10.51 min (S). 
 
4.3.6 Synthesis of N-(1-(3-bromophenyl)ethyl)benzylamine (70) 
 
 
 
The desired product was obtained as a pale white oil. 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.66 (bs, 1H, Ar), 7.49 (d, 1H, J=8 Hz, Ar), 7.45-
7.35 (m, 6H, Ar), 7.30 (t, 1H, J=8 Hz, Ar), 3.88 (q, 1H, J=8 Hz, CH), 3.73 (q, 2H, J=8 Hz, 
CH2), 1.45 (d, 3H, J=8 Hz, CH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 148.22 (Cq), 140.39 (Cq), 130.11 (Ar), 130.06 (Ar), 
129.85 (Ar), 128.43 (2 Ar), 128.11 (2 Ar), 126.48 (Ar), 125.42 (Ar), 122.72 (C-Br), 57.19 
(CH), 51.70 (CH2), 22.78 (CH3). 
HPLC: Chiracel OD-H column, hexane/2-propanol (99:1), flow rate: 0.8 mL/min, 
wavelength detector at 254 nm, tR= 7.93 (R), tR= 9.01 min (S). 
 
 
Experimental Section 
 
 
112 
 
4.4 Immobilization of Homogenous Catalysts 
 
4.4.1 Synthesis of silica-supported catalysts 
 
4.4.1.1 Synthesis of (8S,9S)-(2-trimethoxysilyl)-9-picolinamide(9-deoxi)-epi-
cinchonidine (71) 
 
 
 
In a two-necked round-bottom flask, 196 mg of compound 36 (0.492 mmol) was dissolved 
in anhydrous THF and 0.187 mL of trimethoxysilane (1.476 mmol) and 10 mg of dcpPtCl2 
(0.0246 mmol) were added in this order.343 The mixture was refluxed, under nitrogen 
atmosphere, for 24 h. The solvent was evaporated under reduced pressure on a rotary 
evaporator and the crude product 71 was obtained in quantitative yield as a dark oily solid 
and used without further purification.  
1H NMR (300 MHz, CDCl3) δ (ppm) = 9.28 (bs, 1H, NH), 8.92 (d, 1H, J=3 Hz, H2’), 8.59 
(d, 1H, CH pyridine), 8.49 (d, 1H, CH pyridine), 8.13 (d, 1H, J=6 Hz, H5’), 8.05 (d, 1H, J=6 
Hz, H8’), 7.76-7.73 (m, 2H, H7’, CH pyridine), 7.65 (t, 1H, J=6 Hz, H6’), 7.37 (d, 1H, J=3 Hz, 
H3’), 5.89 (bs, 1H, H9), 3.74-3.71 (m, 2H, H6, H2), 3.60-3.52 (m, 3H, H8, H6, H2), 3.47 (s, 
9H, CH3), 2.35 (bs, 1H, H3), 1.86-1.79 (m, 3H, H4, H5, H7), 1.30-1.25 (m, 2H, H5, H10), 
0.87-0.83 (m, 2H, H7, H11). 
 
4.4.1.2 Synthesis of (8S,9S)-(2-trimethoxysilyl)-9-picolinamide(9-deoxi)-epi-
quinine (71a) 
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Applying the same procedure as described above (see 4.4.1.1) using compound 44 (523 
mg, 1.22 mmol), trimethoxysilane (0.465 mL, 3.66 mmol) and dcpPtCl2 (24 mg, 0.061 mmol), 
the crude product 71a was obtained in quantitative yield as a dark oily solid and used without 
further purification. 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.94 (bs, 1H, NH), 8.72 (d, 1H, J=3 Hz, H2’), 8.52 
(d, 1H, CH pyridine), 8.49 (d, 1H, CH pyridine), 8.05-8.01 (m, 1H, H8’, H5’), 7.74-7.68 (m, 
2H, H7’, CH pyridine), 7.43 (t, 1H, J=6 Hz, H6’), 7.28 (d, 1H, J=3 Hz, H3’), 5.61 (bs, 1H, H9), 
3.96 (s, 3H, CH3), 3.81-3.69 (m, 2H, H6, H2), 3.59-3.51 (m, 3H, H8, H6, H2), 3.33 (s, 
9H,CH3), 2.25 (bs, 1H, H3), 1.86-1.80 (m, 3H, H4, H5, H7), 1.40-1.24 (m, 2H, H5, H10), 
0.99-0.82 (m, 2H, H7, H11). 
 
4.4.1.3 Synthesis of (8S,9S)-(2-trimethoxysilyl)-9-[2-(N-methyl)pyridinium]-(9-
deoxi)-epi-quinine iodide (71b) 
 
 
 
Applying the same procedure as described above (see 4.4.1.1) using compound 45 (338 
mg, 0.592 mmol), trimethoxysilane (0.226 mL, 1.777 mmol) and dcpPtCl2 (12 mg, 0.0296 
mmol), the crude product 71b was obtained in quantitative yield as a dark oily solid and used 
without further purification. 
 
4.4.1.4 Grafting reaction – General procedure343  
 
Commercially available mesoporous silica nanoparticles (1 g) and the properly modified 
organotrimethoxysilane (0.7 mmol) were suspended in anhydrous toluene (15 mL) and 
stirred at reflux for 48 h, under nitrogen atmosphere. The immobilized catalysts were isolated 
by filtration, washed with a mixture of organic solvents (AcOEt, CH2Cl2 and MeOH) and dried 
under vacuum to remove any trace of remaining solvent.  
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4.4.1.4.1 Synthesis of silica-supported (8S,9S)-9-picolinamide(9-deoxi)-epi-
cinchonidine (72) 
 
 
 
Applying the same procedure as described above (see 4.4.1.4) catalyst 37 was 
immobilized onto silica as a white solid, with a loading of 0.4 mmol/g. 
 
4.4.1.4.2 Synthesis of silica-supported (8S,9S)-9-picolinamide(9-deoxi)-epi-
quinine (73) 
 
 
 
Applying the same procedure as described above (see 4.4.1.4) catalyst 44 was 
immobilized onto silica as a white solid, with a loading of 0.5 mmol/g. 
4.4.1.4.3 Synthesis of silica-supported (8S,9S)-9-[2-(N-methyl)pyridinium]-(9-
deoxi)-epi-quinine iodide (74) 
 
 
 
Applying the same procedure as described above (see 4.4.1.4) catalyst 45 was 
immobilized onto silica as a pale yellow solid, with a loading of 0.3 mmol/g. 
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4.4.2 Synthesis of polymer-supported catalysts 
 
4.4.2.1 Synthesis of ((2S,4S,5S)-5-ethylnyl-2-quinuclidinyl)(6-methoxy-4-
quinolinyl) methanol (75) 
 
 
 
In a two-necked round-bottom flask, was prepared a solution of quinine (2 g, 6.2 mmol) 
in anhydrous CH2Cl2, under nitrogen atmosphere. After cooling to 0ºC in an ice bath, a 6M 
bromide solution (12.4 mmol) in anhydrous CH2Cl2 was added dropwise over a period of 15 
minutes. The resulting yellow suspension was vigorously stirred for 1 h at 0ºC and then 1 h 
at room temperature. After this time, 120 mL of petroleum ether was slowly added in order 
to precipitate the 10,11-dibromo derivative. The suspension was stirred for 10 minutes and 
the crude product was collected by filtration and washed with petroleum ether (40 mL). The 
resultant yellowish solid was dried under high vacuum and then used in the next step without 
further purification. The crude product was transferred to a single necked round-bottom flask 
and dissolved in 50 mL of THF. Aliquat (0.6 mmol) was added and, after 5 minutes of stirring, 
powdered potassium hydroxide (6 mmol) was added in one portion. The mixture was stirred 
at 45ºC for 1 hour, then freshly powdered potassium hydroxide (6 mmol) was added again 
and the mixture was stirred for another hour at 45ºC, then for 15 hours at room 
temperature.355 The solids were removed by filtration and washed repeatedly with THF (50 
mL). The filtrates were concentrated under vacuum giving a brownish solid which was 
partially purified by flash column chromatography, eluted with AcOEt/MeOH (10:1). The 
yellowish crude solid obtained was suspended in 80 mL of a mixture of ETP/AcOEt (4:1) 
and vigorously stirred for 24 h at room temperature. The resultant precipitate was filtered, 
washed with a mixture of ETP/AcOEt (10:1, 100 mL) and pure petroleum ether (100 mL), 
and dried under vacuum to give the desired compound 75 as an off-white solid (1.26 g, 3.91 
mmol, 63%). 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.70 (d, 1H, J=3 Hz, H2’), 7.96 (d, 1H, J=6 Hz, H8’), 
7.54 (d, 1H, J=6 Hz, H7’), 7.33-7.29 (dd, 1H, J=6 Hz, H3’), 7.23 (d, 1H, J=6 Hz, H5’), 5.72 
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(bs, 1H, H9), 3.89 (s, 3H, CH3), 3.61 (bs, 1H, H6), 3.42 (m, 1H, H8), 3.24 (m, 1H, H2), 2.98 
(bd, 1H, H6), 2.72 (m, 1H, H2), 2.60 (m, 1H, H3), 1.97 (d, 1H, J=6 Hz, H11), 1.85 (m, 1H, 
H7), 1.50 (m, 1H, H5), 1.28-1.33 (m, 1H, H4). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 158.1, 148.0, 144.7, 131.9, 127.1, 122.0, 118.9, 
101.8, 88.1, 72.4, 69.1, 59.9, 58.3, 56.1, 43.1, 28.0, 27.5, 26.5, 22.8. 
 
4.4.2.2 Synthesis of (8S,9R)-(2-(4-vinylbenzyl)-triazole)-quinine (76) 
 
 
 
In a two-necked round-bottom flask, 300 mg of compound 75 (0.935 mmol) was dissolved 
in anhydrous CHCl3 (12 mL), under nitrogen atmosphere, and then 8.9 mg of copper iodide 
(0.047 mmol) and 1.55 mL of diisopropylethylamine (9.35 mmol) were added. The mixture 
was stirred for 15 minutes at room temperature, then a solution of 4-azidomethylstyrene 
(193 mg, 1.22 mmol) in anhydrous CHCl3 (2 mL) was slowly added. The mixture was stirred 
for 24 hours at room temperature. After this time, 5 mL of a solution of ammonium hydroxide 
33% w/t was added and the mixture was stirred for 10 minutes. The collected organic phase 
was washed with hydrochloric acid 10% w/t (3 x 5 mL), then the aqueous phase was 
collected and washed with a solution of sodium bicarbonate. The organic phase was 
extracted with CH2Cl2 (3 x 10 mL), dried with anhydrous Na2SO4 and filtered. The solvent 
was evaporated under reduced pressure on a rotary evaporator and the crude product 
purified by flash column chromatography, eluted with a mixture of CH2Cl2/MeOH (9:1) to 
(7:3), affording desired compound 76 as a white-off solid (230 mg, 51%). 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.66 (d, 1H, J=4.3 Hz, H2’), 7.95 (d, 1H, H8’), 7.53 
(d, 1H, H3’), 7.33 (d, 2H, J=7.8 Hz, CH styrene), 7.30 (dd, 1H, J=9.1 Hz, H7’), 7.23 (d, 1H, 
J=0.89 Hz, H5’), 7.11 (d, 2H, CH styrene), 7.09 (d, 1H, H11), 6.70 (dd, 1H, CH styrene), 
5.79 (d, 1H, J=17.6 Hz, CH styrene), 5.73 (b, 1H, H3), 5.37 (s, 2H, CH2 styrene), 5.32 (d, 
1H, J=10.9 Hz, CH styrene), 3.87 (s, 3H, CH3), 3.68 (m, 1H, H6), 3.39 (m, 2H, H8), 3.06 (m, 
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1H, H3), 2.79 (m, 1H, H6), 2.11 (bs, 1H, H4), 1.89 (m, 1H, H5), 1.79 (m, 1H, H7), 1.66 (m, 
1H, H5), 1.39 (m, 1H, H7). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 157.9 (C6’), 150.4 (C10), 147.4 (C2’), 146.7 (C4’), 
144.2 (C9’), 138.1 (C styrene), 135.9 (C styrene), 133.9 (C styrene), 131.5 (C8’), 128.2 (C 
styrene), 126.8 (C styrene), 126.5 (C10’), 121.7 (C7’), 120.3 (C11), 118.5 (C3’), 114.9 (C 
styrene), 101.2 (C5’), 70.8 (C9), 59.71 (C8), 55.9 (C2, CH3), 53.8 (C styrene), 43.4 (C6), 
32.9 (C3), 27.8 (C4), 26.8 (C5), 21.5 (C7).  
 
4.4.2.3 Synthesis of (8S,9S)-(2-(4-vinylbenzyl)-triazole)-9-amino(9-deoxi)-epi-
quinine (77) 
 
 
 
Following the procedure used for the synthesis of (8S,9S)-9-amino(9-deoxi)-epi-quinine 
31 (see 4.2.1.3), 227 mg of compound 76 (0.47 mmol) was dissolved in anhydrous THF (8 
mL), under nitrogen atmosphere, and 0.208 mL of triethylamine (1.49 mmol) was added. 
The reaction mixture was cooled to 0ºC in an ice bath and, after 10 minutes of stirring, 0.073 
mL of methanesulfonyl chloride (0.946 mmol) was added dropwise. The mixture as allowed 
to reach room temperature and it was stirred for 5h. After consumption of substrate, 
monitored by TLC, a saturated solution of NaHCO3 (5 mL) was added. The organic phase 
was extracted with CH2Cl2 (3 x 10 mL), dried with anhydrous Na2SO4 and filtered. The 
solvent was evaporated under reduced pressure on a rotary evaporator and crude product 
used without further purification. The pale yellow solid obtained was dissolved in 8 mL DMF 
and then 61.5 mg of sodium azide (0.946 mmol) was added. The mixture was stirred at 80-
85ºC for 18 h. After consumption of substrate, monitored by TLC, the solvent was 
evaporated under reduced pressure in a rotary evaporator. The crude product was dissolved 
in CH2Cl2 and 8 mL of water was added. The organic phase was separated and the aqueous 
phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic phases were dried 
with anhydrous Na2SO4, filtered and concentrated under vacuum affording a brownish solid 
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that was used without further purification. This crude product was dissolved in anhydrous 
THF (5 mL), in a two-necked round-bottom flask, under nitrogen atmosphere. The mixture 
was heated to 50ºC and a solution of triphenylphosphine (186 mg, 0.71 mmol) in anhydrous 
THF (3 mL) was slowly added. The reaction mixture was stirred at 50ºC for 5 hours. After 
this time, the mixture was allowed to reach room temperature and 0.6 mL of distilled water 
was added. The reaction was stirred for another 15 hours at room temperature. After this 
time, the solvent was evaporated under reduced pressure on a rotary evaporator, the crude 
product was diluted in 10 mL CH2Cl2 and a solution of HCl 10% w/t was added up to pH 2. 
The organic layer was washed with CH2Cl2 (2 x 5 mL) and then a solution of NH4OH 33% 
w/t was added up to pH 8. The organic phase was extracted with CH2Cl2 (3 x 10 mL), dried 
with anhydrous Na2SO4 and filtered. The solvent was evaporated under reduced pressure 
on a rotary evaporator and crude product was purified by flash column chromatography, 
eluted with CH2Cl2/MeOH/NEt3 (98:2:1), affording desired compound 77 as an off-white solid 
(59 mg, 26%). 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.71 (d, 1H, J=4.6 Hz, H2’), 8.02 (d, 1H, H8’), 7.64 
(b, 1H, H5’), 7.41 (d, 1H, H3’), 7.40 (d, 2H, CH styrene), 7.38 (d, 1H, J=9.2 Hz, H7’), 7.18 
(d, 2H, J=8.6 Hz, CH styrene), 7.17 (s, 1H, H11), 6.72 (dd, 1H, CH styrene), 5.82 (d, 1H, 
J=17.6 Hz, CH styrene), 5.46 (s, 2H, CH styrene), 5.33 (d, 1H, J=11.4 Hz, CH styrene), 4.62 
(bs, 1H, H9), 3.99 (s, 3H, CH3), 3.54 (dd, 1H, H2), 3.49 (dd, 1H, H2), 3.32 (m, 1H, H6), 3.08 
(m, 1H, H3), 2.93 (m, 1H, H6), 1.92 (bs, 1H, H4), 1.67 (m, 2H, H5), 1.32 (m, 1H, H7), 0.76 
(m, 1H, H7). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 157.7 (C6’), 151.3 (C10), 147.9 (C2’), 146.8 (C4’), 
144.7 (C9’), 138.1 (C styrene), 135.9 (C styrene), 134.1 (C styrene), 131.8 (C8’), 128.8 (10’), 
128.2 (C styrene), 126.8 (C styrene), 121.2 (C7’), 120.2 (C11), 119.9 (C3’), 115.0 (C 
styrene), 102.0 (C5’), 61.6 (C8), 55.8 (CH3), 55.6 (C2), 53.8 (C9), 41.1 (C6), 33.2 (C3), 27.9 
(C4), 27.7 (C5), 26.0 (C7). 
 
4.4.2.4 Synthesis of (8S,9S)-(2-ethynyl)-9-amino(9-deoxi)-epi-quinine (81) 
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Applying the procedure described above (see 4.4.2.3), starting from 400 mg of compound 
75 (1.246 mmol), after only one purification by flash column chromatography eluted with 
CH2Cl2/MeOH (98/2), compound 81 was obtained as a yellowish solid (320 mg, 80%). 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.70 (d, 1H, J=3 Hz, H2’), 7.96 (d, 1H, J=6 Hz, H8’), 
7.54 (d, 1H, J=6 Hz, H7’), 7.33-7.29 (dd, 1H, J=6 Hz, H3’), 7.23 (d, 1H, J=6 Hz, H5’), 5.72 
(bs, 1H, H9), 3.89 (s, 3H, CH3), 3.61 (bs, 1H, H6), 3.42 (m, 1H, H8), 3.24 (m, 1H, H2), 2.98 
(bd, 1H, H6), 2.72 (m, 1H, H2), 2.60 (m, 1H, H3), 1.97 (d, 1H, J=6 Hz, H11), 1.85 (m, 1H, 
H7), 1.50 (m, 1H, H5), 1.28-1.33 (m, 1H, H4). 
13C NMR (100 MHz, CDCl3) δ (ppm) = 158.1, 148.0, 144.7, 131.9, 127.1, 122.0, 118.9, 
101.8, 88.1, 72.4, 69.1, 59.9, 58.3, 43.1, 28.0, 27.5, 26.5, 22.8. 
 
4.4.2.5 Synthesis of (8S,9S)-(2-ethynyl)-9-picolinamide(9-deoxi)-epi-quinine (82) 
 
 
 
Applying the previously described mixed anhydride method (see 4.2.1.8.2), compound 
82 was synthesized from 200 mg of amine 81 (0.622 mmol), picolinic acid (87 mg, 0.622 
mmol), NEt3 (121 μL, 0.871 mmol) and isobutyl chloroformate (81 μL, 0.928 mmol) in 
anhydrous THF. The crude product was purified by silica gel column chromatography, eluted 
with a mixture of CH2Cl2/MeOH (95:5), giving the desired product as an off-white solid (194 
mg, 73%). 
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.78 (d, 1H, J=3 Hz, H2’), 8.67 (d, 1H, CH pyridine), 
8.10 (d, 1H, CH pyridine), 7.96 (d, 1H, J=6 Hz, H8’), 7.79 (d, 2H, J=6 Hz, H7’, CH pyridine), 
7.48 (d, 1H, J=3 Hz, CH pyridine), 7.33-7.29 (dd, 1H, J=6 Hz, H3’), 7.23 (d, 1H, J=6 Hz, 
H5’), 5.72 (bs, 1H, H9), 3.89 (s, 3H, CH3), 3.49-3.38 (m, 2H, H6, H2), 3.23 (bs, 1H, H8), 
2.81-2.69 (m, 2H, H6, H2), 2.31 (bs, 1H, H3), 1.63-1.58 (m, 3H, H4, H5, H7), 1.38-1.25 (m, 
1H, H5), 0.89-0.86 (m, 1H, H7). 
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13C NMR (100 MHz, CDCl3) δ (ppm) = 164.25, 158.1, 157.5, 148.0, 147.3, 144.7, 141.4, 
131.9, 127.1, 122.4, 122.0, 121.9, 118.9, 101.8, 88.1, 72.4, 69.1, 59.9, 58.3, 43.1, 28.0, 
27.5, 26.5, 22.8.  
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5. References 
 
 
 
 
 
 
 
 
 
 
 
 
“The important thing is not to stop questioning. Curiosity has its own reason for existing” 
Albert Einstein 
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